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Abstract 
Diabetes mellitus is characterized by a chronic increase in blood glucose levels due to a 
dysfunction of carbohydrate, fat and protein metabolism, which in turn are the result of 
insulin resistance and/or insulin action disturbances. Its cardinal symptoms include 
polyuria, thirst and weight loss; its long term complications include neuropathy, 
nephropathy, and retinopathy. It is predicted that this rate will increase to 9.9% of the 
adult population by 2030. Although the rate of new cases of End Stage Renal Disease 
(ESRD) in 2011 decreased 4.2% compared to the year 2010, nephropathy due to diabetes 
continued to be the most common cause of ESRD in the USA. In this study a genome-
wide association approach has been performed to identify loci associated with diabetic 
nephropathy (DN) and variation in estimated Glomerular Filtration Rate (eGFR) value in 
three distinct ethnic groups, i.e. African American, Mexican American and European 
American; additionally, the effect of sex has also been studied to reveal potential sex 
dependency on the loci associated with DN and eGFR value. Dataset provided in "The 
Family Investigation of Nephropathy and Diabetes” (FIND) Study, contains genotype of 
1454 individuals with DN and 1168 individuals without DN .After conducting genome-
wide association analyses, in this study, the strongest association with DN and/or eGFR 
values have been detected on the regions located on the 2p, 2q, 3q, 4q, 5q, 7q, 8q, 9q, 
12q, 14q, 15q and Xq chromosomes.  
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Chapter I 
Introduction 
I.1. Diabetes Mellitus 
Diabetes mellitus is characterized by a chronic increase in blood glucose level due to a 
dysfunction of carbohydrate, fat and protein metabolism, which in turn are the result of 
insulin resistance and/or insulin action disturbances. Its cardinal symptoms include 
polyuria, thirst and weight loss. Amputation and foot ulcers due to peripheral neuropathy, 
renal failure as the result of nephropathy, and blindness due to retinopathy are among its 
serious long-term complications (Alberti, Zimmet 1998). Considering the underlying 
cause, diabetes mellitus is classified in two main classes: Insulin Dependent Diabetes 
Mellitus (IDDM) or Type 1 Diabetes (T1D) and Non-Insulin Dependent Diabetes 
Mellitus (NIDDM) or Type 2 Diabetes (T2D). T1D is caused primarily by autoimmune 
processes, which leads to pancreatic β-cell islets destruction. Affected individuals are 
susceptible to ketoacidosis and require insulin to survive. T2D is caused either due to 
dysfunction of insulin secretion or to increased insulin resistance (Alberti, Zimmet 1998). 
I.2. Clinical Presentation of T1D 
Insulin secretion in T1D is very little or there is complete insulin deficiency and patients 
are dependent on exogenous insulin (Sherwin 2004). Majority of the patients are 
symptomatic and present with polyuria, polydipsia, polyphagia, and weight loss; they 
may also develop ketoacidosis. Evidence that supports an autoimmune nature of this type 
of diabetes include association with specific genes (e.g. HLA), presence of the 
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autoantibodies to insulin, glutamic acid decarboxylase, tyrosine phosphatases IA-2 and 
IA-2β and islet cells (Sherwin 2004, American Diabetes Association 2004). T1D is 
further sub-classified in autoimmune and idiopathic accounting for approximately 90% 
and 10% of all cases of T1D respectively (Maraschin 2012). Other autoimmune 
conditions such as Hashimoto's thyroiditis, Grave's disease and pernicious anemia may 
also be found in the patients with T1D (American Diabetes Association 2004).     
I.3. Clinical Presentation T2D   
Although patients with T2D have some insulin secretion, most of the patients with T2D 
are asymptomatic at evaluation; however fatigue, dizziness and blurred vision are 
common in these patients. Classical symptoms of hyperglycemia including polyuria, 
polydipsia and weight loss are seen in some of T2D (Sherwin 2004, American Diabetes 
Association 2004). Since T2D is a long lasting disease, patients may develop 
cardiovascular complications, retinopathy, neuropathy or nephropathy. Other common 
symptoms include erectile dysfunction in males and those related to vaginitis or 
generalized pruritus in females. Hypertension, dental decay and gingivitis are commonly 
seen in these patients. Most of the patients are overweight or obese. When significant 
insulin resistance exists, acanthosis nigricans is seen in some patients (Imam 2012). 
Although almost all of the children diagnosed as diabetic had type 1 diabetes in the past, 
recently it has been reported that the frequency of T2D is considerably increasing in this 
group. Most of these children are overweight or obese at the time of diagnosis and show 
glycosuria without classical symptoms (American Diabetes Association 2000). 
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I.4. Diagnosis of DM 
American Diabetes Association described three ways for diagnosis of diabetes mellitus: 
1) Random Plasma Glucose ≥200 mg/dl together with classical symptoms i.e. polyuria, 
polydipsia, and weight loss, 2) Fasting Plasma Glucose ≥126 mg/dl and 3) Oral Glucose 
Tolerance Test ≥200 mg/dl 2 hours after glucose is taken orally (American Diabetes 
Association 2004). Recently, measurement of the HbA1c has been recommended as an 
alternative method for the diagnosis of T2D by the World Health Organization and the 
American Diabetes Association (WHO 2011, American Diabetes Association 2010).  
I.5. Complications of DM 
The death rates due to heart disease and stroke have been reported to be 2 to 4 times 
higher in adults with diabetes compared to those without diabetes. It has also been 
estimated that 67% of adults with diabetes had high blood pressure, i.e. ≥ 140/90 mmHg 
(NDIC 2011). Diabetes mellitus is the leading cause of renal failure and blindness among 
adults; 44% and 28.5% of adults with diabetes developed diabetic nephropathy (DN) and 
diabetic retinopathy (DR) respectively. More than 200,000 people were on dialysis or had 
a kidney transplant in 2008 in the USA (NDIC 2011). Diabetes mellitus accounts for 
about 35% of cases with chronic renal failure. Approximately 30% of individuals with 
T2D have an increase in urinary albumin excretion (30-300 mg/24h) or overt albuminuria 
(>300 mg/24h) when they are diagnosed to have diabetes. DN is manifested initially by a 
rise in Glomerular Filtration Rate (GFR), then an increase in urinary albumin excretion 
and eventually decreased GFR (Estacio, Schrier 2001). Progressive renal function failure 
follows persistent proteinuria. Hypertension, nephrotic syndrome and end stage renal 
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failure are further clinical manifestations. Fluid retention, hyperkalemia, neurogenic 
bladder, and eventually coronary artery disease are among ESRD complications; the 
latter is the main cause of mortality in these patients (de Francisco 1999). Nervous 
system complications including pain or impaired sensation in the feet or hands, delayed 
digestion, erectile dysfunction and carpal tunnel syndrome have been found in 60% to 
70% of diabetics. Periodontal disease and complications of pregnancy are also more 
common in individuals with diabetes. Diabetic ketoacidosis and nonketotic coma are 
acute life-threatening complications when diabetes is not controlled (NDIC 2011).  
I.6. Epidemiology of DM 
Following economic growth and urbanization which has led to change in lifestyle, 
particularly because lack of physical activity and an increase in the number of obese 
people, diabetes mellitus continues to be one of the most common chronic diseases in the 
world. The global prevalence rate of diabetes among adults has been estimated to be 
8.3%, or 366 million adults, in 2011 (American Diabetes Association 2013). North 
America and the Caribbean countries were the second most prevalent regions after the 
Middle East and the North African countries. It is predicted that this rate will increase to 
9.9% of the adult population, or 552 million adults, by 2030 (American Diabetes 
Association 2013). In Canada, there were 2.7 million adults, or 10.8% of the population, 
living with diabetes in 2011 and estimated to increase to 3.7 million people, i.e. 12.8% of 
the population, by 2030 (Whiting, Guariguata et al. 2011). According to a study of the 
American Diabetes Association, the total cost of diabetic care was estimated to be about 
$245 billion in 2012, with direct costs of $176 billion and indirect costs of $69 billion, 
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this shows a 41% increase when compared to the estimates of 2007 (American Diabetes 
Association 2013). In Canada, the total costs for diabetics are estimated to be more than 
CDN$8.14 billion in 2016 (Ohinmaa, Jacobs et al. 2004). 
Currently T2D is more prevalent in the developing countries rather than in the developed 
countries compared to the past (Shaw, Sicree et al. 2010). In addition, individuals with 
T2D in the developing countries are younger compared to the type 2 diabetics in the 
developed countries (Shaw, Sicree et al. 2010). Not surprisingly, due to fast economic 
growth, nutrition transition and urbanization in a short time, Asia, particularly China and 
India, are encountered as the 'diabetic epicenter' worldwide (Chan, Malik et al. 2009). 
Individuals who emigrated from Middle East to Sweden have been reported to have 
greater prevalence of DM than native Swedes (Wandell, Johansson et al. 2008). Although 
usually T2D had been considered as an adulthood disorder, it is becoming more common 
in adolescents and children (Pinhas-Hamiel, Zeitler 2005). Younger individuals who have 
T2D are at more risk for developing early and chronic complications (Chen, Magliano et 
al. 2011). Risk factors for T2D have been divided to modifiable and non-modifiable. 
Modifiable risk factors include, but are not limited to, overweight or obesity, physical 
inactivity, dietary factors, hypertension, intrauterine environment and abnormal lipids. 
Family history of T2D, ethnicity, sex and age are among non-modifiable risk factors 
(Chen, Magliano et al. 2011). 
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I.7. Pathogenesis of T1D 
T1D, also known as IDDM or juvenile-onset diabetes, accounts for approximately 5% of 
all diagnosed diabetes in adults (NDIC 2011); genetic, environmental factors and 
infections are known to be involved in its development (Acharjee, Ghosh et al. 2013).  
I.7.1. Genetic Factors 
The role of genetics in T1D has been revealed by many family and twin studies. For 
example, high concordance rate has been reported among twin pairs in a study conducted 
in Finland (Hyttinen, Kaprio et al. 2003). HLA genes located on the chromosome 6 have 
been identified to be associated with the development of T1D; HLA DR3 and DR4 alleles 
increase the risk of T1D (Erlich, Valdes et al. 2008). HLA molecules are involved in the 
binding procedure of antigens to T lymphocytes (Bluestone, Herold et al. 2010). IDDM2 
gene and CTLA-4 gene, by affecting insulin gene expression in the thymus and impact on 
T cell function and regulation respectively, are possibly involved in the development of 
T1D (Sherwin 2004). Parts of innate immune system including B cells, natural killer cells 
and macrophages have been reported to be involved in the development of T1D through 
autoimmunity processes and their interaction with adaptive immune system (Ting, Bansal 
et al. 2012). Genes in the Human Leukocyte Antigen (HLA) region within the major 
histocompatibility complex (MHC) on chromosome 6 have been reported to be correlated 
with T1D (Concannon, Erlich et al. 2005). Disparities in alleles frequencies could explain 
the genetic susceptibility variation in different races, e.g. the statistically significant high 
frequency of protective heterozygous and homozygous alleles have been reported in 
Chinese 72% and 22% respectively. In White Americans the frequency of the 
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homozygous allele, which is associated with greater risk, has been found to be about 
96%. These findings are consistent with the observed incidence rates of T1D in these 
populations, i.e. 0.7 and 15.8 persons per 100,000 per year in Chinese and White 
Americans, respectively (Bao, Wang et al. 1989). It has also been reported that a 
polymorphic locus near the insulin gene (Bell, Horita et al. 1984), and polymorphism in 
the protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene (Bottini, Musumeci 
et al. 2004) are associated with T1D. There is evidence that changes in the cytotoxic T 
lymphocyte antigen 4 gene (CTLA4), probably through their effects on T-cell activity, 
could be involved in the causation of some autoimmune disorders such as IDDM (Ueda, 
Howson et al. 2003). The interleukin 2 receptor alpha (IL2RA) gene region has also been 
determined to be associated with T1D (Lowe, Cooper et al. 2007). Since the incidence 
rate of T1D differs considerably not only between countries, e.g. in Finland the risk is 
about 35 times higher than in Japan (LaPorte, Tajima et al. 1985), but also within very 
similar ethnic groups that are located in different geographical locations, e.g. three times 
more in Finland than in Estonia, environmental and geographic factors could have 
particular impacts on its development (Zimmet, Alberti et al. 2001). 
I.7.2. Environmental Factors 
Since the pairwise concordance rates among identical twins vary between 13% and 33%, 
environmental factors must play essential role in the progression of the T1D (Kaprio, 
Tuomilehto et al. 1992). These factors include diet, viral infections and toxins. The 
potential role of cow's milk, which contains bovine insulin, in the development of T1D 
has been investigated in different studies. It is supposed that it acts through β-cell 
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autoimmunity process by exposing the β-cell and insulin autoantigens (Sabbah, Savola et 
al. 2000, Vaarala, Atkinson et al. 2008). Coxsackievirus B (CVB), mumps, rubella, 
cytomegalovirus (CMV) and enterovirus infections, possibly because of their effects on 
the β-cell autoimmunity, have been reported to be associated with an increased incidence 
of T1D (Ting, Bansal et al. 2012). It has been documented that while T1D incidence rate 
was low in the first half of the 20th century, it increased in the second half (Gale 2002). 
This increase may not only be explained by diagnosis improvements; either the increased 
survival of children with T1D resulted in pooling putative genes, or changes in 
environmental factors are considered as possible mechanisms (Krolewski, Warram et al. 
1987). In animal models, diet, specifically gluten-free has been determined to have an 
impact on the incidence of T1D (Buschard 2011). The protective effect of a gluten-free 
diet at the risk of autoimmune disorders in humans has also been investigated (Cosnes, 
Cellier et al. 2008). Interaction between environmental factors and MHC might explain 
the difference in the incidence rate of T1D before and after 1980 (Badenhoop, Kahles et 
al. 2009). It has been shown that there is an association between enteroviral infection and 
the incidence of T1D (Dahlquist, Ivarsson et al. 1995). It has also been reported that the 
incidence rate of T1D significantly increased after an outbreak of coxsackievirus B5 
infection (Wagenknecht, Roseman et al. 1991). 
I.8. Pathogenesis of T2D 
T2D, also known as NIDDM or adult-onset diabetes, is a common complex disease that 
is caused by a disturbance in glucose metabolism, which initially starts due to the 
resistance to insulin and eventually may lead to a dysfunction of the pancreas; T2D 
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accounts for about 90% to 95% of diabetic cases in adults (NDIC 2011). Like other 
complex diseases several factors are involved in the development of T2D; the impacts of 
lifestyle, environmental and genetic factors have been well investigated. 
I.8.1. Genetic Factors 
Family and twin studies have been used to identify genetic predisposition in T2D. In one 
study, investigators concluded that there is 100% concordance rate for type 2 diabetes 
among monozygotic twins (Barnett, Eff et al. 1981). On the other hand, only less than 
50% of obese individuals who are insulin resistant develop diabetes; this suggests that 
only some of the patients who are at risk are susceptible to develop the disease (Stumvoll, 
Goldstein et al. 2007). In monogenic forms of diabetes such as Maturity Onset Diabetes 
of Youth (MODY), the genetic basis has been revealed although the majority of patients 
are polygenic. Peroxisome proliferator activated receptor gamma (PPAR-γ), insulin gene, 
calpain 10, and intestinal fatty acid binding protein 2 (FABP 2) are some of the candidate 
genes correlated with the development of T2D (Sherwin 2004). The prevalence rate of 
T2D has been demonstrated to be different within and between migrant groups 
suggesting the effect of the nature/nurture phenomenon (Abouzeid, Philpot et al. 2013). 
The same genotypes might result in different phenotypes among individuals with the 
same origin who live in different countries, indicating genetic and/or environmental 
components are involved for the same trait. For example, it has been detected that 
diabetic "Japanese Americans" with a "Pro/Pro" genotype of the peroxisome proliferator-
activated receptor (PPARγ) had greater BMI and fasting serum insulin levels compared to 
diabetic "native Japanese". On the other hand, the expression of the "Ala-allele" genotype 
10 
 
was the same between two groups (Nemoto, Sasaki et al. 2002, Leonetti, Fujimoto 1989). 
In contrast, the prevalence rate of diabetes was similar between Indians who immigrated 
to Britain and those who lived in India (Patel, Vyas et al. 2006). African ancestry in three 
US population cohorts, i.e. Atherosclerosis Risk in Communities (ARIC) Study, 
Multiethnic Cohort (MEC) and the Jackson Heart Study (JHS), has been reported to be 
significantly associated with a higher odds ratio of diabetes, even after adjusted for age, 
sex, study centre, BMI and socioeconomic status (Cheng, Reich et al. 2012). Native 
American ancestry in Hispanic Americans (Parra, Hoggart et al. 2004) and in Mexicans 
(Martinez-Marignac, Valladares et al. 2007) has been identified to be correlated with 
higher risk of T2D.  European ancestry among central Mexicans and Colombians has 
been shown to be associated with an increased risk of T2D (Florez, Price et al. 2009). 
I.8.2. Environmental Factors 
The fact that diabetes genotype, i.e. individual who has susceptibility genes for T2D, 
does not result in diabetes phenotype in all cases implies that clinical presentation of T2D 
depends on environmental factors (Leahy 2005). Association of obesity and lack of 
physical activity with T2D have been well studied (Hu, Manson et al. 2001). Modern 
lifestyle, characterized by high calorie intake and less physical activity, increases the 
incidence rate of T2D; it has been discussed that these factors affect on glucose 
homeostasis by increasing insulin resistance or β-cell dysfunction. In the presence of 
genetic predisposition, these factors increase the risk of hyperglycemia (Leahy 2005). 
Migrant studies support the concept that environmental factors are involved in the 
development of T2D. Moving from countryside and rural areas to urban areas has been 
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reported to be associated with severe obesity followed by an increase in the incidence of 
T2D; interestingly, it has been shown that the frequency of T2D decreased by moving 
back to prior lifestyle. Examples include Australian Aboriginals, and Pima Indians 
(O'Dea 1984). Increase in the incidence of T2D in China and India, due to the movement 
to the metropolitans, is another example (Weiss, Dziura et al. 2004). Insulin resistance 
occurs when the effects of insulin are impaired (Dinneen, Gerich et al. 1992). Many 
patients with impaired fasting glucose (IFG) or with T2D have hyperinsulinemia; 
therefore it has been proposed that the insulin resistance results in hyperglycemia 
(Stumvoll, Goldstein et al. 2007). Insulin resistance is associated with overweight and 
obesity; in obese individuals nonesterified fatty acids (NEFA), which are originated in 
adipocytes, are increased and result in more resistance to the insulin effects (Boden 
1997). Insulin bonds to receptor that shows tyrosine kinase activity, and in turn activates 
the insulin receptor substrate (IRS) proteins. Serine and/or threonine phosphorylation 
results in the reduction of the tyrosine kinase activity of the insulin receptor which in 
turns can inhibit IRS protein activity; this mechanism is considered to be involved in the 
development of insulin resistance (Stumvoll, Goldstein et al. 2007). Adipose tissue is the 
main source of the NEFA, tumor necrosis factor-α (TNFα) and interleukin 6 (IL-6); 
increased levels of these products impair insulin signal process and can cause insulin 
resistance (Rajala, Scherer 2003, Ravussin, Smith 2002). β-cell dysfunction results in 
insulin secretion below the normal levels in patients with T2D. In the presence of insulin 
resistance (resulted from obesity or lack of physical activity) the pancreas secretory 
function is decreased that could cause impaired glucose tolerance (IGT) or diabetes 
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(Stumvoll, Goldstein et al. 2007). There is evidence indicating a linkage between fetal 
life and diseases developed at adolescence. It has been reported that a lower birth weight 
(LBW) was related to the development of T2D later in life (Barker, Hales et al. 1993, 
Whincup, Kaye et al. 2008); in premature infants, regardless of their weight for 
gestational age, insulin sensitivity had been reduced (Hofman, Regan et al. 2004). 
Statistically significant association has been found between famine exposure during fetal 
life and hyperglycemia in adulthood (Li, He et al. 2010). A change of lifestyle from 
traditional which included more activities to modern ways (i.e. more static and sedentary) 
could be associated with an increase of insulin resistance that in turn predisposes one to 
the development of obesity and T2D (O'Dea 1991); urbanization and “western food” 
have also been reported to be correlated with a higher prevalence of T2D (Ostbye, Welby 
et al. 1989). On the other hand, the effectiveness of lifestyle interventions in reducing the 
incidence rate of T2D has also been well documented (Knowler, Barrett-Connor et al. 
2002, Bo, Ciccone et al. 2007, Diabetes Prevention Program Research Group, Knowler et 
al. 2009). Although familial aggregation supports genetic contribution to T2D, it should 
be noted that many studies have shown the protective effects of increased physical 
activity, appropriate diet and lifestyle modification in proceeding from IGT to diabetes 
(Pan, Li et al. 1997, Tuomilehto, Lindstrom et al. 2001, Kosaka, Noda et al. 2005, 
Kontogianni, Liatis et al. 2012, Ramachandran, Snehalatha et al. 2013). Reviews of 
studies conducted to evaluate the impact of environmental chemicals and/or pollutants on 
the risk of T2D show that there is evidence suggesting a high exposure of persistent 
organic pollutants (POPs) (Taylor, Novak et al. 2013), arsenic (Maull, Ahsan et al. 2012) 
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mercury (He, Xun et al. 2013) and Organophosphorus Compounds (OPCs) 
(Pournourmohammadi, Farzami et al. 2005) could increase the risk of diabetes. 
I.9. Genetics of DM  
Different epidemiologic studies including international variation, migrant/admixture 
studies, ethnic/racial differences, the effects of age, sex and time on incidence rate, 
familial aggregation and twin/adoption studies are used to investigate the genetic 
component of complex disorders such as diabetes (Thomas 2004). It has been shown that 
polymorphisms in the calpain-10 (CAPN10) regions are associated with the risk of T2D 
(Horikawa, Oda et al. 2000); however, there is considerable difference in the observed 
allele frequencies in CAPN10 between African and non-African populations, suggesting 
that this difference could be partly the result of adaptation and be explained by natural 
selection (Fullerton, Bartoszewicz et al. 2002). Regardless of ethnicity, geographic and 
environmental diversities, the transcription factor 7-like 2 (TCF7L2) gene has been 
demonstrated to be associated with the development of T2D, which supports the 
existence of genetic predisposition as a potential risk factor (Cauchi, El Achhab et al. 
2007). A considerably lower frequency of a protective haplotype of human 
immunoglobulin G system, i.e. Gm
3;5,13,14
, in Pima and Papago Indians ancestors strongly 
supports the effect of ethnicity and genetic mixture on the prevalence of T2D (Knowler, 
Williams et al. 1988). It has been estimated that 15.7 million or 10.2% of all non-
Hispanic Whites, ages 20 years or older, and 4.9 million (18.7%) of all Non-Hispanic 
Blacks, ages 20 years or older, suffered from diabetes in the United States in 2010 (NDIC 
2011), indicating considerable prevalence variation between different racial and ethnic 
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groups. In the multiethnic cohort study of diet and cancer, T2D prevalence was more than 
two times higher in native Hawaiians, Latinos, AA and Japanese compared to EA 
(Maskarinec, Grandinetti et al. 2009). However, allele frequencies of risk markers did not 
show any greater genetic risk in these populations (Waters, Stram et al. 2010); therefore, 
the effect size of these variants is controversial. Asian-Australians in the Fremantle 
Diabetes Study had a similar T2D prevalence compared to the general population 
although they had significantly lower BMI and more paternal history of diabetes (Tan, 
Davis et al. 2013). In contrast, the prevalence of T2D has been shown to be significantly 
higher among south Asian migrants in Norway (Jenum, Holme et al. 2005). 
I.9.1. Population-Based Studies 
Since families share environment and genes, familial clustering of T2D and its traits 
could be used to determine genetic contribution in T2D. It has been shown that in 
addition to lower high density lipoprotein (HDL) cholesterol concentrations, greater 
fasting plasma insulin concentration and BMI, Caucasian first degree relatives of 
diagnosed diabetic individuals living in the UK had T2D prevalence rate four times 
higher, which could be the result of genetic and/or environmental predisposition among 
the relatives of probands (Shaw, Purdie et al. 1999). In the Framingham Offspring Study, 
it has been reported that when both parents were diabetics the risk of T2D among 
offspring was six fold higher than those without any parental diabetes history, which 
supports the genetic transmission pattern of T2D (Meigs, Cupples et al. 2000). In a cohort 
of young Chinese, the Hong Kong Family Diabetes Study, the risk of Impaired Glucose 
Tolerance (IGT) and diabetes were 1.5 and 4.3 higher respectively among siblings of 
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probands; obesity, dyslipidaemia and hypertension rates were also more frequent in these 
relatives compared to the general population (Li, Ng et al. 2006). In a study in Tunisia, it 
has been detected that the prevalence of T2D in the siblings of probands was 45% 
compared to 8.9% in the general population; 34% of diagnosed diabetics had one affected 
parent, and maternal transmission was two times greater than paternal (Arfa, Abid et al. 
2007, Whiting, Guariguata et al. 2011). In a large-scale study, conducted in Sweden, the 
genetic basis of familial aggregation has been investigated.  The relative risk (RR) was 
2.03 in offspring of one affected parent similar to the risk for singleton siblings (2.77) but 
increased to 5.35 when two parents were affected. When biological parents of adoptees 
were probands, the risk for adoptees was 2.16 while the risk did not change in adoptees 
when their adopted parents were affected (Hemminki, Li et al. 2010).  
I.9.2. Twin Studies  
To distinguish between genetic (liability or proportion due to common genes) and 
environmental (environmentality or the proportion due to a shared environment) 
components involved in the development of a complex disease, twins are identified 
among affected individuals to compare the concordance/discordance rates of 
monozygotic (MZ) and dizygotic (DZ) to estimate the heritability (Thomas 2004). 
In the first study, conducted in England, in which twins had been differentiated according 
to the etiology of diabetes, i.e. T1D vs. T2D, and tested for glucose tolerance, it was 
found that 90.6% of MZ twins had been concordance for T2D (48 out of 53, proband 
concordance rate: 64%); the authors concluded that, by considering the age of the 
affected twins, genetic predisposition was more involved in the development of T2D 
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(Barnett, Eff et al. 1981). In a study of 250 MZ American male twins, it has been 
reported that the concordance rate for T2D in MZ twins was 58% and the concordance 
rate of impaired glucose tolerance has been detected in 65% of non-diabetic MZ twins; 
therefore, MZ twin brothers had six fold higher risk for developing T2D suggesting a 
strong genetic correlation among affected persons (Newman, Selby et al. 1987). First 
large scale study outside Western countries revealed that 38 out of 46(83%) and 4 out of 
10 (40%) MZ and DZ diabetic pairs were concordance for T2D respectively in Japan 
(Committee on Diabetic Twins 1988) and the probandwise concordances for T2D have 
been reported to be 31.6% and 10.0% among MZ and DZ male twins respectively in a 
Finnish study (Kaprio, Tuomilehto et al. 1992). In the Danish Twin Register, the 
probandwise and pairwise concordance rates were significantly higher among MZ pairs 
than DZ just when IGT had been considered in addition to T2D. The study showed 
significantly high heritability for BMI (r = 0.68 for MZ versus r = 0.28 for DZ) and 
weight (r = 0.78 for MZ versus r = 0.39 for DZ), i.e. h
2
 equals to 0.80 and 0.78 
respectively, indicating a major role of genetic predisposition in the variations of these 
traits; r specifies “Interclass Correlation” that measures resemblance within twin pairs 
and h
2
 identifies “Heritability” that states the fraction of the whole variation of a trait 
attributable to genetic variation, which is calculated as ℎ2 = 2 × (𝑟𝑀𝑍 − 𝑟𝐷𝑍) (Poulsen, 
Kyvik et al. 1999). In a more recent study the probandwise concordances reported to be 
0.58 and 0.11 among MZs and DZs respectively and the genetic risk derived from 
concordance ratio has been estimated to be 5.3 for T2D (Condon, Shaw et al. 2008). 
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I.9.3. Mode of Inheritance  
Different inheritance patterns in T1D have been discussed in different studies. In one 
study, it has been reported that 55% to 60% of affected type 1 diabetic pairs of siblings 
shared two identical HLA haplotypes, 40% shared one haplotype, and only very few 
shared zero haplotypes. Supposing that the related gene is frequent in the population, this 
pattern follows autosomal recessive inheritance (Rubinstein, Ginsberg-Fellner et al. 
1981). In contrast, autosomal dominant pattern fitted better in studying the inheritance of 
Juvenile diabetes in Caucasian and American Blacks (MacDonald 1980). In another 
study, it has been proposed that the phenotype of T1D could be best explained by the 
gene dosage effect; it has been estimated that the penetrance rate was 0.71 in individuals 
having two haplotypes, compared to 0.065 in cases with one haplotype (Spielman, Baker 
et al. 1980). However, many studies support heterogeneity concept regarding the mode of 
inheritance in T1D (Rotter 1981). It has been shown that there is strong association 
between one allele of ACE gene and T2D in Indian population; the best mode of 
inheritance has been reported to be recessive and multiplicative (Singh, Naz et al. 2006). 
Although Plasma Cell-1 (PC1) gene and its polymorphism have been reported to be 
associated with T2D and insulin resistance, neither a recessive nor an additive mode of 
inheritance could be found in the Moroccan population. However, in the presence of 
obesity, its polymorphism showed association with T2D in both models (El Achhab, 
Meyre et al. 2009). Additive mode of inheritance has been identified between TCF7L2 
gene allele, and the treatment result in type 2 diabetics (Holstein, Hahn et al. 2011). 
Mendelian inheritance model with a single major gene effect was the best model, which 
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explained the aggregation of overt albuminuria in Pima Indian families (Imperatore, 
Hanson et al. 1997). A Mendelian major gene effect and multifactorial inheritance has 
been identified in the clustering of albuminuria and urinary albumin excretion (UAE) in 
Caucasian families with T2D (Fogarty, Hanna et al. 2000). 
I.10. Genetics of Diabetic Nephropathy 
It has been reported that 41% of the siblings of probands with T1D and diabetic renal 
disease developed ESRD while none of the siblings of probands without DN had such 
extreme renal dysfunction (Seaquist, Goetz et al. 1989). In Pima Indians, protienuria was 
found in 45.9%, 22.9% and 14.3% of the offspring if both, one or neither parents had 
T2D and proteinuria, respectively (Pettitt, Saad et al. 1990). The siblings of insulin 
dependent diabetics with nephropathy were five times more likely to develop elevated 
microalbuminuria or clinical nephropathy (Borch-Johnsen, Norgaard et al. 1992). 19% of 
non-insulin dependent African American diabetics with ESRD had a first degree relative 
with ESRD; if second and third degree relatives were also included, the risk of 
developing ESRD increased eight times (Freedman, Tuttle et al. 1995). The risk of 
diabetes in offspring of Pima Indian parents with DN, independent of age at the onset of 
parental diabetes, has been found to be 2.5 times higher than offspring of diabetic parents 
without diabetic renal disease suggesting that DN could be a positive predictor for 
developing diabetes in the offspring (McCance, Hanson et al. 1995). Familial clustering 
of ESRD, with different causes, has also been identified in White Americans; if a first, 
second or third degree relative had ESRD, the individual risk of ESRD was increased 3.5 
times (Spray, Atassi et al. 1995). Persistent proteinuria incidence rate was 2.5 times 
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higher in the siblings of T1D probands with advanced diabetic renal disease compared to 
the siblings of probands without renal complication or with microalbuminuria (Quinn, 
Angelico et al. 1996). 
I.11. Strategies of Gene Identification  
There are different methods to identify genes, which are correlated with diabetes and DN.  
I.11.1. Candidate Gene Studies 
Candidate gene studies rely mostly on the present understanding of causal relationship 
between the potential causative gene and the disease condition; Freedman et al. and 
Bowden reviewed these candidate genes (Bowden 2003, Freedman, Bostrom et al. 2007). 
Endothelial Nitric Oxide Synthase (eNOS) gene by hemodynamic mechanisms, possibly 
through intraglomerular hypertension, has been demonstrated to be involved in the 
development of ESRD in Japanese population (Suzuki, Nagase et al. 2000). Growth 
factor and cytokine genes have also been reported that play a role in the development and 
progression of diabetic nephropathy in type 2 diabetics. Kallikrein genes, with the effect 
on release of bradykinin, have been shown to be associated with DN in AA population 
(Bowden 2003). The role of inflammation in the pathogenesis of DN has also been 
studied, and genes encoding cytokines such as Tumor Necrosis Factor (TNF), Interleukin 
1 receptor antagonist (IL-1Ra) and interleukin 1 β (IL-1β) are other candidate genes that 
might be associated with DN (Lee, Lee et al. 2005). Manganese superoxide dismutase 
(Mn-SOD) gene, by its impact on the oxidative stress mechanism, has been identified to 
be associated with albuminuria in Korean type 2 diabetics (Lee, Choi et al. 2006). 
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Angiotensin Converting Enzyme (ACE), through renal renin-angiotensin system, has 
been reported to be related with DN (Ng, Tai et al. 2005, Ng, Placha et al. 2006). 
Engulfment and Cell Motility 1 (ELMO1) gene, possibly through the accumulation of 
extracellular matrix proteins in the glomeruli, has been found to be associated with 
chronic renal dysfunction in Japanese (Shimazaki, Kawamura et al. 2005, Shimazaki, 
Tanaka et al. 2006); variants of ELMO1 gene have also been reported to be associated 
with ESRD in AA (Leak, Perlegas et al. 2009). 
I.11.2. Genome-Wide Linkage Studies  
In the linkage studies about 400 genetic markers, which are uniformly located across the 
genome, are genotyped in the relatives with DN. Statistical methods are used to identify 
chromosomal regions that are segregated with DN; the basic concept is that DN 
contributing genes could be found within these regions regardless of their previous 
known biological function. The logarithm of odds (LOD) score is used to determine the 
probability that these locations are being inherited with the disease of interest (Bowden 
2003, Freedman, Bostrom et al. 2007). Linkage analyses, both two-point and multi-point, 
of Pima Indian sib-pairs with T2D revealed that two loci on chromosome 7, i.e. D7S500 
and D7S1804, were strongly linked with nephropathy; aldose reductase (ALDR1), T-cell 
receptor β-chain (TCRBC) and constitutive endothelial nitric oxide synthase 3 (NOS3) 
genes are located in this region that might be involved in the development of DN 
(Imperatore, Hanson et al. 1998). In Turkish families, genome wide scan showed strong 
linkage with DN with maximum LOD score of 6.1 in a region located on the 
chromosome 18q when all participants included in the analysis. A region between 
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D18S43 and D18S50 markers on chromosome 18 has been reported to have a strong 
linkage with DN in type 2 diabetes; the Krupple-like zinc-finger gene 236 (ZNF236), the 
expression of which is glucose dependent, was located on this region (Vardarli, Baier et 
al. 2002). A genome scan of African American family members with NIDDM and ESRD 
revealed three susceptible loci on chromosomes 3q, 7p and 18q linked with diabetic 
nephropathy; with maximum LOD score of 1.43, the region on chromosome 7p showed 
the strongest linkage with DN in the entire sample. In addition, when Ordered Subset 
Analysis (OSA) with phenotypic traits was performed (age at ESRD onset), a region on 
the chromosome 3q has been found to have a combined LOD score of 4.55 in a subset of 
families (Bowden, Colicigno et al. 2004). Non-parametric linkage analysis (NPL) and 
OSA revealed strong linkage in African Americans with renal disease on the 
chromosomes 2q (individuals with earliest age at ESRD onset) and 10q (individuals with 
latest age at ESRD onset) with the LOD score of 3.05 and 2.47 respectively (Freedman, 
Bowden et al. 2005). Familial aggregation of renal function has been studied through a 
genome-wide linkage scan of patients with T2D and revealed significant heritability, 
(ℎ2 = 0.29 − 0.47) of estimated (GFR) among diabetic relatives. Regions within 
chromosome 2 and chromosome 10 have been reported to be linked with GFR 
aggregation with LOD score of 4.1 and 3.1 respectively (Placha, Poznik et al. 2006). The 
results of these studies are summarized in the table 1. 
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Table 1: The results of the linkage studies 
Study DM Sample Size Marker CHR Method p-value LOD 
Imperatore et al. T2D 135 D7S500 7q M-NPL 2.00E-04 2.73 
Vardarli et al. T2D 368 D18S469 18q M-NPL 9.00E-03 6.14 
Bowden et al. T2D 355 D7S3051 7p S-NPL 1.00E-02 1.43 
Freedman et al. T2D 1023 D13S796* 
D2S1391** 
D10S1248*** 
13q 
2q 
10q 
M-NPL/OSA 2.40E-03 
1.68E-02 
4.86E-02 
4.94 
3.05 
2.47 
Placha et al. T2D 406 D2S1384 2q M-VCL 6.20E-06 4.01 
M-NPL: Multiple Non Parametric Linkage, S-NPL: Single Non Parametric Linkage, OSA: Ordered 
Subsets Analysis, M-VCL: Multiple Variance Component Linkage, LOD: Logarithm of Odds, *subset by 
BMI (High), **subset by age at diagnosis of ESRD (early onset), *** subset by age at diagnosis of ESRD 
(late onset)  
I.11.3. Genome-Wide Association Studies  
In Genome-Wide Association Study (GWAS) the allele frequency is compared in 
individuals with the condition of interest, such as disease status or specific phenotype (i.e. 
cases), and those without this condition (i.e. controls) to identify associations between 
single nucleotide polymorphisms (SNPs) and traits of interest. Association studies could 
be conducted at population level to compare unrelated individuals, indeed the correlations 
of observed phenotypes and observed marker alleles would be investigated. The power of 
these studies is good only if common causal variants are under investigation i.e. the 
minor allele frequency (MAF) is not too small, Common-Disease Common-Variant 
(CDCV) hypothesis is hold and population is on Hardy-Weinberg Equilibrium (HWE) 
(Balding 2006, Balding, Bishop et al. 2007, Ziegler, Konig 2010). In the GoKinD 
collection, a genome-wide association scan of T1D revealed 11 SNPs variants of four loci 
located on chromosomes 7p, 9q, 11p and 13q to be associated with DN; rs10868025 on 
chromosome 9q, near the 4.1 protein ezrin, radixin, moesin (FERM) gene, showed the 
strongest association; in addition, some variations in ELMO1 gene have also been 
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reported to be associated with DN in Caucasians (Pezzolesi, Katavetin et al. 2009), 
(Pezzolesi, Skupien et al. 2010). In another study conducted in African Americans, 25 
SNPs have been identified to be associated with ESRD in T2D; rs6930576 (𝑝 = 7.04 ×
10−7) showed the strongest association with ESRD and is located on the chromosome 6q 
within the SAM and SH3 domain containing 1 (SASH1) gene (McDonough, Palmer et al. 
2011). In an attempt to replicate the results of a previous study conducted in European 
T1D, which found 3 SNPs associated with DN, in Japanese population only one 
(rs7588550, p = 0.0126, odds ratio (OR) = 0.79, 95 % confidence interval: 0.65–0.95) of 
3 SNPs has been reported to be significantly associated with DN in Japanese T2D, 
although the effect direction was reverse; this SNP is located on the chromosome 2q near 
the  erb-b2 receptor tyrosine kinase 4 (ERBB4) gene that encodes one of the type 1 
receptor tyrosine kinase subfamily (Maeda, Imamura et al. 2013). The results of these 
three studies are summarized in the table 2. 
Table 2: Strongest SNPs associated with DN in GWA Studies  
Study* Type of 
DM  
Sample 
Size 
SNP Gene CHR  Method p-value 
Pezzolesi et al. T1DM 1705 rs10868025 FRMD3 9q GWAS 5.00E−07 
McDonough et al. T2DM 2993 rs6930576 SASH1 6q GWAS 7.04E−07 
Maeda et al. 
(replication study) 
T2DM 2300 rs7588550 ERBB4 2q Logistic Regression 
Analysis 
1.26E−02 
*these studies were case-control designed  
I.11.4. Present Study    
In this study The Family Investigation of Nephrology and Diabetes (FIND) study dataset 
has been used to perform a genome-wide association approach to identify loci associated 
with DN as a dichotomous trait and changes in estimated GFR (eGFR) which is a 
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quantitative variable in three distinct ethnic groups including 1454 cases with diabetes 
and kidney disease selected from FIND probands, and 1168 controls from unrelated 
FIND family members.  
The goal of this study is to determine genetic contribution in the development of diabetic 
nephropathy and variation in eGFR across the whole genome among those having T2D. 
The main hypothesis is that since T2D is a polygenic disorder (Imam 2012, Thomas 
2004), abundant SNPs located on the various genes could be found that are associated 
with DN and eGFR values in type 2 diabetics. In addition, because the dataset used in this 
study includes information of three distinct ethnicities, differences could also be 
determined to identify whether the potential SNP(s) and/or gene(s) associated with 
DN/eGFR are located on the same regions, or presented in different loci in each race, i.e. 
AA, MA and EA; finally, sex dependency in each group could also be detected. 
Therefore, the assumptions are that SNP(s)/gene(s) do exist in Type 2 Diabetics of FIND 
study cases, although they might be located in different loci and chromosomes in 
different ethnic group, and it could be possible to detect sex dependency as well. Several 
quality control metrics were applied to this data to avoid biases due to study design and 
errors in genotype calling, which could potentially lead to systematic biases in genetic 
case-control association studies and result in increasing the number of false-positive and 
false-negative associations. Since the dataset which is used in this study provided 
information for each race separately, quality control metrics would also be applied for 
each race separately.  
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The FIND investigators have used a case-control design with inclusion/exclusion criteria 
for their study, and I performed GWA analyses to detect potential association(s) between 
SNP(s) and DN or eGFR values. Although no SNPs were found significantly associated 
with diabetic nephropathy in any ethnic groups, the strongest ones associated with DN 
and eGFR values, reported in this study, are summarized in the table 3 and table 4 
respectively. 
Table 3: Top Associated SNPs with DN in different races and sexes  
Ethnicity 
Sample Size SNP Gene CHR*
 
χ2 p-value GC**  
African Americans 
All Together 
Females 
Males 
864 rs1285582 NUP62CL Xq 29.55 5.46E-08 9.23E-08 
573 rs6705592 SLC8A1-AS1 2p 21.80 3.02E-06 4.27E-06 
291 rs3857190 In. variant*** 4q 23.80 1.07E-06 1.30E-06 
European Americans 
All Together 
Females 
Males 
       
763 rs4774390 RORA 15q 27.67 1.44E-07 1.69E-07 
414 rs2069347 CCNG1 5q 24.98 5.79E-07 5.79E-07 
349 rs1239908 In. variant*** 12q 26.89 2.16E-07 3.94E-07 
Mexican Americans 
All Together 
Females 
Males 
       
1000 rs17067207 In. variant*** 5q 23.42 1.30E-06 1.81E-06 
603 rs2923173 In. variant*** 5q 19.00 1.31E-05 1.60E-05 
397 rs1106228 In. variant*** 9q 24.74 6.55E-07 6.77E-07 
*CHR: Chromosome, **Genomic Control (GC) is an easy way to detect, and adjust for population stratification, 
***Intergenic Variant  
Table 4: Top Associated SNPs with eGFR variation in different races and sexes  
Ethnicity 
Sample Size SNP Gene CHR Β* p-value GC**  
African Americans 
All Together 
Females 
Males 
864 rs1285582 NUP62CL Xq 14.07 9.97E-08 1.10E-07 
573 rs17820651 ds. variant*** 2q 24.91 3.57E-06 3.76E-06 
291 rs243294 NPAS3 14q 23.04 9.81E-07 1.03E-06 
European Americans 
All Together 
Females 
Males 
       
763 rs4774390 RORA 15q 13.15 3.64E-07 3.73E-07 
414 rs4675095 IRS1 2q -36.36 5.62E-06 5.91E-06 
349 rs2118063 In. variant**** 8q -17.60 7.46E-07 9.94E-07 
Mexican Americans 
All Together 
Females 
Males 
       
1000 rs4680068 CLRN1 3q 62.21 1.83E-08 1.83E-08 
603 rs10949778 ds. variant*** 7q 63.23 9.11E-08 9.11E-08 
397 rs4904196 In. variant**** 14q 22.28 3.75E-07 3.75E-07 
*B: Beta i.e. regression coefficient, **Genomic Control (GC), **Downstream Gene Variant, ***Intergenic Variant  
26 
 
Chapter II 
Genome-wide association study to identify single nucleotide polymorphisms 
associated with diabetic nephropathy in FIND study 
II.1. Introduction 
Since in the FIND study, data is available for three distinct ethnicities (AA, MA and EA), 
in this work a genome-wide association study has been performed to identify loci 
associated with diabetic nephropathy in three distinct ethnic groups. A genome-wide 
association study (GWAS) has been done in multi-ethnic groups including 1454 cases 
with diabetes and kidney disease selected from FIND probands and 1168 controls from 
unrelated FIND family members. 
Although the rate of new cases of ESRD in 2011 decreased 4.2% compared to the year 
2010, nephropathy due to diabetes continued to be the most common cause of ESRD in 
the USA accounting for 44.7% of new cases. The incident rate of ESRD in diabetics 
varied from 122.3 per million of the population to 405.6 per million between different 
races; African Americans had the highest rate followed by Hispanics; the rate was ≈ 3.32 
times higher than in whites and ≈ 1.28 times higher than in Hispanics (USRDS 2013). 
Considerable variation regarding prevalence rate of diabetes and diabetic nephropathy 
between different racial and ethnic groups has also been reported (NDIC 2011).  
II.2. Materials and Methods 
The Family Investigation of Nephrology and Diabetes (FIND) 
The Family Investigation of Nephrology and Diabetes (FIND) has been established by 
the National Institute of Health (NIH) to investigate the genetic contribution in the 
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development and progress of diabetic nephropathy. Eight U.S. clinical centers have been 
involved for recruitment of eligible participants among four distinct ethnic groups. Two 
main strategies for detecting susceptibility genes include: 1) a family-based linkage 
study, and 2) mapping by admixture linkage disequilibrium (MALD) in case-control 
group. Individuals entered to the study have been classified in two groups: “Family” and 
“MALD” (Family Investigation of Nephropathy and Diabetes Research Group 2003). 
The “Family” study has been used for linkage analysis among those with DN who either 
their both parents are alive or have a diabetic sib. On the other hand, in the “MALD” 
study a case-control design has been used for mapping by admixture linkage 
disequilibrium (Family Investigation of Nephropathy and Diabetes Research Group 2003, 
Knowler, Coresh et al. 2005).  
Admixture mapping or Mapping by Admixture Linkage disequilibrium (MALD) method 
is based on the concept that long haplotype blocks are generated by gene flow during 
admixture, and is used to identify linkage disequilibrium (LD) of MALD markers 
(≈2000-3000) and disease genes. Some points are required to be considered in MALD 
method: the disease incidence rate should be very different between the parental 
populations, frequency difference of disease-causing alleles should be measureable 
between the parental populations, at least admixture should be two generations old, and 
markers should be selected appropriately. Since in AAs the relative risk of NIDD and 
ESRD differs between the parental populations (i.e. African ancestry and European 
ancestry) MALD approach could be useful for African-America population to identify 
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disease genes following linkage studies and HapMap-based association scans (Smith, 
O'Brien 2005).   
Linkage Disequilibrium (LD) is a property that identifies the tendency of an allele of one 
SNP to be inherited with an allele of another SNP in the population, when these two 
alleles (at nearby loci) are seen together on the same chromosome more often than 
expected by chance the loci are said to be in disequilibrium. A specific set of alleles on 
the chromosome is known as a haplotype. D՛ and 𝑟2are the two most common statistics of 
LD. D՛ measures the recombination events between markers and ranges from 0 to 1, 
where 0 indicates complete linkage equilibrium (frequent recombination happened) and 1 
indicates complete LD (there is no historical recombination). 𝑟2is defined as the squared 
correlation coefficient between 2 SNPs and is correlated with the allele frequencies, 
𝑟2ranges also from 0 to 1. If 𝑟2equals to 1, it would indicate perfect LD. In this case, only 
one of the two markers can be genotyped to identify the allelic variation (Ardlie, 
Kruglyak et al. 2002). LD can be assessed by using HapMap genotype database. The 
International HapMap Project provided a genome-wide database of common SNPs 
variants, which are required to identify genetic association with clinical phenotypes; 
samples of 11 human populations have been genotyped for more than 1.5 million SNPs 
(International HapMap Consortium 2005). 
The most common used methods to correct the multiple- testing results are described 
briefly: 1) In Control of Family-Wise Error Rate (FWER) or Bonferroni correction the 
significant level is adjusted considering the number of independent tests; to reach the 
traditional significant level of 0.05, when there are m independent tests, α is calculated 
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either as 𝛼 = 1 − (1 − 0.05)1 𝑚⁄  known as Sidak correction, or as 𝛼 ≈ 0.05 𝑚⁄  known 
as Bonferroni correction. 2) In permutation test, cases and controls are randomly changed 
by each other and all m tests will be calculated again; this procedure will be repeated 
typically 1000 times. 3) In Bayesian method, Bayes' rule is used to assess the probability 
that null hypothesis is true when a test is significant; it depends on the study power, false 
positive rate and the prior probability that null hypothesis is true. 4) Benjamini and 
Hochberg introduced False Discovery Rate (FDR) method; in this method α is set at an 
appropriate level (driven from data), which is used for controlling the expected number of 
false discoveries in m tests (So, Sham 2011). 
The main goal of FIND study has been to detect and find genes that are involved in the 
development of DN. To be able to consider genetic differences, African Americans 
(AAs), European Americans (EAs), Mexican Americans (MAs), and American Indians 
were recruited; mostly, FIND collected family members information, along with case and 
control subjects. Three approaches have been defined to detect disease-causing alleles: 
genome-wide linkage study by investigating diabetic family members concordant or 
discordant for DN, MALD and analysis the associations of certain alleles with DN in a 
population (Knowler, Coresh et al. 2005).        
The results of the first linkage analysis, using a microsatellite marker-based genome scan 
in FIND participants, have shown linkage to DN in regions of chromosomes 7q, 10p, 14q 
and 18q (Iyengar, Abboud et al. 2007). It has also been reported that regions on 
chromosomes 1q, 2p, 7q, 8q and 18q were linked to changes in eGFR in Mexican 
Americans population; however, in American Indians the linkage was seen on 
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chromosome 11p, and in African Americans it was on chromosome 15q (Schelling, 
Abboud et al. 2008). Interval on chromosome 6p has also been identified to be linked 
with DN among European Americans (Igo, Iyengar et al. 2011). Another study revealed 
evidence of linkage between eGFR variation and regions on chromosomes 20q (SNP: 
rs736264) and 15q (SNP: rs2928714) in Mexican Americans and European Americans, 
respectively (Thameem, Igo et al. 2013).   
The sample provided by NIH is a population study. Initially, it was supposed to detect 
potential impact of polymorphisms in the engulfment and cell motility 1 (ELMO1) and 
silent information regulator 1 (SIRT1) genes on diabetic nephropathy in different ethnic 
groups through authorized access to the dataset granted by NIH (please refer to the 
appendix 1 for this approval); however, due to resources limitations, specially funding the 
project, and since the title of the FIND database i.e. “The Family Investigation of 
Nephropathy and Diabetes” is broad, in the present study, I conducted a GWAS to 
determine potential SNPs associated with DN and eGFR values.  
The characteristics of participants are presented in table 5. This sample includes 
information about 2622 individuals (1454 cases with DN and 1168 controls without DN) 
who participated in the FIND study. Family members who received insulin and/or oral 
hypoglycemic medicines, and those without diabetes history with hemoglobin A1C 
(HbA1C) ≥6.0% were categorized as diabetic. Overt proteinuria with proteinuria ≥500 
mg/24h or albuminuria ≥300 mg/24h, together with a protein/creatinine ratio ≥0.5 or 
urine albumin/creatinine ration ≥0.3 was defined as nephropathy (Knowler, Coresh et al. 
2005).  
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The dataset provides information such as medical history (5 variables: diabetes, high 
blood pressure, kidney failure, leg amputation, and retinopathy), anthropometry 
measurements (4 variables: current and maximum height and weight), laboratory tests (18 
variables: history and laboratory urine protein excretion, serum creatinine, urine protein, 
urine albumin sign, urine albumin, urine creatinine, PCR, ACR, and GFR), 
sociodemographic data including sex, race, and age; medication history (2 variables: 
taking Angiotensin-converting enzyme (ACE) inhibitors or Angiotensin II Receptor 
Blockers (ARBs) and taking insulin); high blood pressure; duration of diabetes, kidney 
failure and high blood pressure; and the age of onset of diabetes and kidney failure (for 
details of variables please see appendix 2).  
Table 5: Participants Characteristics 
 DN (+) RF (-) DN (+) RF (+) DN (-) RF (-) 
Male / Female (%) 110(46.4)/127(53.6) 535(44)/682(56) 387(33.1)/781(66.9) 
Age (SD) 58.39 (11.01) 61.32 (11.02) 59.53 (10.22) 
Ethnicity    
         African American (%) 36 (15.2) 545 (44.8) 278 (23.8) 
         European American (%) 
(%) 
57 (24.1) 282 (23.2) 424 (36.3) 
        Mexican American (%) 144 (60.8) 390 (32) 466 (39.9) 
         Total 237 1217 1168 
Diabetes Age of Onset (SD) 40.60 (12.02) 38.57 (12.78) 41.83 (11.33) 
RF Age of Onset (SD) ------------------------ 58.23 (11.31) ------------------------ 
Diabetes Duration (SD) 17.79 (7.72) 22.82 (9.19) 17.44 (7.70) 
RF Duration (SD) ------------------------ 2.94 (2.59) ------------------------ 
Lab_HbA1C (SD) 8.01 (2.14) 7.01 (1.65) 7.96 (1.88) 
Lab_GFR (SD) 46.20 (30.97) 14.82 (20.85) 86.64 (39.35) 
Lab_Serum Creatinine (SD) 2.08 (1.28) 7.18 (3.47) 0.90 (0.24) 
Lab_Urine Protein (SD) 414.06 (488.54) 189.09 (253.06) 8.88 (8.89) 
Lab_Urine Albumin (SD) 228.02 (331.12) 81.25 (117.11) 3.45 (8.42) 
Lab_Urine Creatinine (SD)  84.92 (59.03) 98.64 (71.49) 94.31 (67.06) 
Lab_PCR (SD) 7.12 (24.48) 2.72 (3.60) 0.49 (7.45) 
Lab_ACR (SD) 6.44 (55.83) 1.54 (1.91) 0.05 (0.86) 
DN: Diabetic Nephropathy, RF: Renal Failure, Lab: Laboratory, SD: Standard Deviation 
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II.3. Subjects 
In this case-control study, two criteria were drawn up to select case subjects, one with 
firm inclusion criteria and one with moderate inclusion. The FIND principal 
investigators, coinvestigators, program coordinator in eight clinical centers and a Genetic 
Analysis and Data Coordinating Center well-defined the inclusion and exclusion criteria 
as follow (Family Investigation of Nephropathy and Diabetes Research Group 2003, 
Knowler, Coresh et al. 2005).   
The firm cases were selected from FIND probands or siblings if they had DN or met one 
or more of the following criteria:  
a) Albumin-to-Creatinine ratio (ACR) ≥ 0.3  
b) Protein-Creatinine ratio (PCR) ≥ 0.5  
c) Glomerular Filtration Rate (MDRD formula) ≤ 60  
d) Serum Creatinine ≥ 1.6 mg/dL for Males, or ≥ 1.4 mg/dL for Females  
The moderated cases were selected from FIND probands or siblings if they had azotemic 
and normal proteinuria, based upon the following criteria:  
a) ACR ≤ 0.03 
b) GFR ≤ 60, Serum Creatinine ≥ 1.6 mg/dL for Males, or ≥ 1.4 mg/dL for 
Females. 
Controls for this case-control study were selected from the unrelated FIND family 
members who were long term (≥10 years) diabetics with healthy kidney function. The 
method included selection based on one or more of the following criteria:  
a) ACR ≤ 0.03, PCR ≤ 0.05, GFR ≥ 60  
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b) Serum Creatinine ≤ 1.6 mg/dL for Males, or ≤ 1.4mg/dL for Females. 
Based on these subject selection criteria, participants were divided into 1454 cases (with 
DN) and 1168 controls (without DN).  
II.4. Genotyping and Quality Control Methods 
DNA samples for eligible cases and controls were genotyped with Affymetrix 6.0 chip.  
Several quality control (QC) metrics were applied to this data to avoid biases due to study 
design (i.e. case-control) and errors in genotype calling, which potentially could lead to 
systematic biases into genetic case-control association studies and result in an increased 
number of false-positive and false-negative associations; to decrease the false positive 
associations, individuals and SNPs with high error rates are removed before applying 
statistical analyses. These QC steps would be implemented both at the individual level 
and marker level (Anderson, Pettersson et al. 2010).  
In this study the thresholds used for filtering are as below: at individual level, those with 
sex inconsistency (discordant sex information), a missing rate of more than 3% (missing 
genotype or heterozygosity rate outliers) are not included in the analyses. Linkage 
disequilibrium (LD) is calculated to measure the dependency between SNPs, and is 
mostly reported as 𝑟2which is the square of the Pearson correlation coefficient. If 𝑋𝐴 is 
the value of one allelic locus and 𝑋𝐵 is the value of the second allelic locus, the standard 
transform of the covariance in allelic value between the loci is called the Pearson 
correlation coefficient and calculated as  𝑟𝐴𝐵 =
𝐶𝑜𝑣(𝑋𝐴 ,𝑋𝐵)
√𝑉𝑎𝑟(𝑋𝐴)𝑉𝑎𝑟(𝑋𝐵)
 = 
𝐷𝐴𝐵
√𝑓𝐴𝑓𝑎𝑓𝐵𝑓𝑏
; therefore 
𝑟2 =
𝐷2
𝑓𝐴𝑓𝑎𝑓𝐵𝑓𝑏
 , where D is the covariance in allelic value between the alleles of a pair of 
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loci, fA is the marginal allele frequency of allele “A” and fa is the marginal allele 
frequency of allele “a” at locus one, fB is the marginal allele frequency of allele “B” and 
fb is the marginal allele frequency of allele “b” at locus two (Balding, Bishop et al. 
2007). Sharing a common ancestry is related to the observed level of LD. High level of 
LD is found when loci are almost linked, and low level of LD is seen in unlinked loci 
with independent ancestry when r2equals to 1, it means there is perfect LD (Balding, 
Bishop et al. 2007). Two-locus Identity by Descent (IBD) could be used to measure the 
shared ancestry between two loci and refers to relatedness, it measures the probability of 
having a single common ancestor at both loci when two chromosomes are selected 
randomly and is expressed as Pr (𝑄𝑖
𝑘 ≡  𝑄?́?
?́?│𝐺), where 𝑄𝑖
𝑘 is allele k in individual I, G is 
a set of observed genotypes on the pedigree and ≡ denotes IBD, i ≠ i/ and k ≠ k/ (Balding, 
Bishop et al. 2007). Theoretically, IBD = 1 shows monozygotic twins or duplicates, in 
first degree relatives IBD equals to 0.5, IBD = 0.25 is expected in  second degree 
relatives and  IBD = 0.125 indicates third degree relatives. In this study IBD greater than 
0.1875 is considered to identify duplicated or related individuals; it means halfway 
between third and second degree relatives (Anderson, Pettersson et al. 2010). Therefore, 
duplicated or related individuals (with 𝑟2 greater than 0.1875) are also excluded in 
analyses. To detect population stratification or divergent ancestry, between group IBS 
differences by using permutation test, IBS similarity matrix and multidimensional scaling 
plots are performed (Anderson, Pettersson et al. 2010, Purcell 2009, Purcell 2010, 
Purcell, Neale et al. 2007). Population stratification could be detected by using Devlin 
and Roeder method (Devlin, Roeder 1999). In this method, named Genomic Control 
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(GC), inflation factor λ value would identify the presence or absence of population 
substructure; i.e. the expected λ will be 1 if there is no population stratification and λ 
greater than 1 indicates population structure. A robust estimate of λ is obtained by ?̂? = 
𝑚𝑒𝑑𝑖𝑎𝑛(𝜒1
2,𝜒2
2,…,𝜒𝐿
2)
0.456
 , where 𝜒1
2, 𝜒2
2, … , 𝜒𝐿
2 are Pearson 𝜒2tests of L unlinked markers 
(Devlin, Roeder 1999); therefore genomic inflation factor (λ) based on median 𝜒2 is also 
reported. Finally, from the "nearest neighbor" scores distribution, individuals with less 
than 4 standard deviation units are considered "outliers" and removed before analyses 
(Purcell, Neale et al. 2007, Purcell 2010).     
At marker level, markers with excessive missing genotype rate (SNPs with a call rate of 
less than 95%), markers that show a significant deviation from Hardy-Weinberg 
equilibrium (HWE) in controls (SNPs with a P value threshold of less than 0.0001 for 
HWE) and those with a low minor allele frequency (SNPs with MAF of less than 0.05) 
are not included in analyses. There was not any SNP with significantly (𝑝 < 0.00001) 
different missing genotype rates between cases and controls (Anderson, Pettersson et al. 
2010, Purcell 2010).   
A pruned subset of SNPs was generated that were in near linkage equilibrium with each 
other based on the variance inflation factor (VIF). The VIF equals  
1
1−𝑅2
 ,where R2 is the 
multiple correlation coefficient for a SNP regressed on all other SNPs. Three parameters 
were used to create this subset: 1) window size in SNPs = 50, 2) the number of SNPs to 
shift the window at each step = 5 and 3) the VIF threshold =2. (Purcell 2010). 
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After removing individuals with sex discordant, the sex codes were imputed based on the 
SNP data. To identify duplicated or related individuals, the pairwise IBS metrics, without 
imposing any thresholds, were calculated.  
Since the data provided in the FIND study does not differentiate T1D from T2D 
(Knowler, Coresh et al. 2005), and the peak incidence of T1D onset is in adolescence and 
most of these patients are insulin dependent and symptomatic (Herold, Vignali et al. 
2013), individuals with age of onset less than 20 who received insulin were excluded 
before statistical analyses to make the study population more homogenous considering 
T2D although it could decrease the power of the study; additionally, one female 
European American with Lab-GFR equivalent to 1112.418 was detected as an extreme 
outlier and excluded from analyses. To determine SNPs that could be sex dependent, all 
statistical analyses were conducted once for both sexes together and once for each sex 
separately. Finally, because the dataset, which is used in this study, provides information 
for each race separately, quality control metrics would also be applied for each race 
separately.          
II.5. Statistical Analyses 
For statistical analyses I used P-link (Purcell 2009), R (R Core Team 2013) and SPSS. In 
P-link, the functions used for analyses include: check-sex, missing, genome (IBD), 
remove (sub setting), impute-sex, indep (pruning), extract, exclude (sub setting), hardy 
(HWE), nonfounders, freq (frequency), pheno (quantitative phenotype i.e. eGFR), ibs 
(IBS group-difference empirical p-values), cluster, mds-plot, assoc (association) and 
adjust. In R, the following functions were used to generate the plots and sub sets: read 
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table, sub setting, scaling plots and creating text files. To create some tables, mean, 
max/min, standard deviation, frequency functions were used in SPSS.    
After filtering applied to the dataset, loci associated with diabetic nephropathy among 
T2D are identified using several statistical analyses in plink software (Purcell 2009, 
Purcell, Neale et al. 2007) for both categorical and quantitative traits although the 
original dataset is based on the dichotomous outcome variable. In the FIND study 
participants are divided into cases and controls regarding the categorical trait of diabetic 
nephropathy as outcome variable; therefore, to be able to use a quantitative outcome 
variable as well, additionally, the data provided in the phenotypic files of FIND study are 
used; the eGFR values was computed as a continuous (quantitative) outcome variable. 
Several equations have been developed to estimate GFR; in Cockcroft-Gault method, 
eGFR in mL/min/1.73 𝑚2 is computed based on the creatinine clearance in mL/min 
adjusted to 1.73 𝑚2. Creatinine clearance (Ccr) is derived by using  the equation:  
𝐶𝑐𝑟 = 
(140−𝑎𝑔𝑒)×(𝑤𝑒𝑖𝑔ℎ𝑡)×(0.85 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒)
72 × 𝑆𝑐𝑟 (𝑚𝑔 100 𝑚𝐿)⁄  
 , where Ccr is in mL/min, age in years, weight in 
kilograms, and Scr (serum creatinine) in mg/dL (Cockcroft, Gault 1976).  
In the Modification of Diet and Renal Disease (MDRD) study, a four variable formula 
was developed to estimate GFR as: 𝐺𝐹𝑅 = 186 × (𝑆𝑐𝑟)
−1.154 × (𝑎𝑔𝑒)−0.203 ×
(0.742 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒) × (1.210 𝑖𝑓 𝐴𝐴), or: 𝐺𝐹𝑅 = 175 × (𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑 𝑆𝑐𝑟)
−1.154 ×
(𝑎𝑔𝑒)−0.203 × (0.742 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒) × (1.210 𝑖𝑓 𝐴𝐴), where GFR is in mL/min/1.73 𝑚2, 
Scr in mg/dL, age in years, and AA indicates African American (Levey, Bosch et al. 
1999, Levey, Coresh et al. 2007). In the FIND study, four variable MDRD formula was 
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used to compute eGFR; the eGFR value for those with kidney failure has been set to 5 
mL/min/1.73 𝑚2 (Thameem, Igo et al. 2013).   
In this study, association between SNPs and the dichotomous or categorical trait has been 
analyzed through the Chi-square test; correction for multiple testing has also been 
considered.         
Regarding quantitative outcome, a linear regression model was considered; then, 
association tests have been conducted for quantitative outcome i.e. eGFR to detect the top 
associated SNPs with the continuous trait and by using a regression coefficient (β) and a 
multiple correlation coefficient (𝑅2) contingency table method, i.e. a Chi-square test, the 
associations have been adjusted for multiple testing.  
To prevent elongation, only the log files of p-link analyses in African Americans are 
stated in appendix 3. The other log files are available upon request.   
II.6. Results 
II.6.1. Genome-wide association scans for single SNPs associated with diabetic 
nephropathy in type 2 diabetics - FIND study: 
II.6.1.1. African Americans 
The number of SNPs and individuals before and after filtering that are indicated in the 
section “II.4.” are summarized in table 6. 
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Table 6: The Results of Quality Control Metrics in AAs 
 Before Filtering After Filtering 
Number of SNPs 932534 782810 
Number of Cases 581 426 
Number of Controls 278 209 
Number of Males 291 199 
Number of Females 573 436 
 
If cases and controls are selected from a population with different ancestries and allele 
and disease frequency rates differ in subpopulations, the results could be false positive 
(Marchini, Cardon et al. 2004, Wu, DeWan et al. 2011); therefore, population 
stratification is a main concern in GWAS case-control studies. As mentioned in section 
“II.4.”, permutation test to detect between group IBS differences and multidimensional 
scaling plots have been used in this study to assess population stratification (Purcell, 
Neale et al. 2007, Anderson, Pettersson et al. 2010, Purcell 2010). To test the population 
structure, permutation test for between group IBS differences was conducted; after 
calculating the pairwise IBS distances among all individuals, assuming a binary 
phenotype, the differences between and within cases and controls could be verified 
(Purcell 2009, Purcell 2010). The result is reported in the table 7, and figure 1 shows the 
multidimensional scaling plots. 
  
40 
 
Table 7: Permutation Test, IBS Differences among all AAs 
Between-group IBS (mean, SD) = 0.817981, 0.00336465 
In-group (2) IBS (mean, SD) = 0.81839, 0.00293358 
In-group (1) IBS (mean, SD) = 0.817598, 0.00367504 
Approximate proportion of variance between group = 0.00155461 
IBS group-difference empirical p-values 
No Description Empirical p-value 
T1 Case/control less similar 0.0137299 
T2 Case/control more similar 0.98628 
T3 Case/case less similar than control/control 0.98632 
T4 Case/case more similar than control/control 0.0136899 
T5 Case/case less similar 0.98635 
T6 Case/case more similar 0.0136599 
T7 Control/control less similar 0.0136299 
T8 Control/control more similar 0.98638 
T9 Case/case less similar than case/control 0.9863 
T10 Case/case more similar than case/control 0.0137099 
T11 Control/control less similar than case/control 0.9816 
T12 Control/control more similar than case/control 0.0184098 
Between-group: case/control, group 1: control/control, group 2: case/case 
 
Using a fixed 10,000 permutations, P-link permutes case/control label, and recalculates 
between-group metrics considering average IBS within that group. The “Permutation 
Test, IBS Differences” tables show mean and standard deviation of each group first; and 
then, the proportion of variance between groups is computed following by 12 separate 
tests with self-description labels. This table could be used to identify whether cases and 
controls are from two distinct populations or not (Purcell 2009, Purcell 2010).       
To display any potential clustering within a population, " − −𝑚𝑑𝑠 − 𝑝𝑙𝑜𝑡 𝑘" function 
together with " − −𝑐𝑙𝑢𝑠𝑡𝑒𝑟" function, embedded in P-link, creates a file that contains one 
row per individual including Family ID, Individual ID, Position on the first dimension, 
Position on the second dimension and so on, depending on the defined number of 
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dimensions "𝑘" to be extracted. Plotting the values on one dimension against the values 
on the other one will generate a scatter plot that could be useful to detect any clustering; 
it is supposed that when population stratification exists, separate clusters would be 
formed (Purcell 2009, Purcell 2010). In “Multidimensional scaling plots” figures, “X” 
axis represents the position on the first dimension denoted by “mds[, 1]” and “Y” axis is 
the position on the second dimension denoted by “mds[, 2]. 
Figure 1: Multidimensional scaling plots in all AAs 
 
Considering the empirical p-values, approximate proportion of variance between group, 
multidimensional plots, which reveals one cluster, and the value of λ, equals to 1.03567, 
it could be stated that population stratification does not exist in this sample. 
In GWAS, multiple tests to assess associations between phenotype and genotype, 
multiple genetic loci and multiple phenotypes result in testing a large number of 
hypotheses that in turn could cause increase of the type I error rate (So, Sham 2011). 
Therefore, several methods developed for multiple-testing correction to estimate the 
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significant level in GWAS; The Wellcome Trust Case Control Consortium: 5 ×
10−7(Wellcome Trust Case Control Consortium 2007), Dudbridge and Gusnanto: 
7.2 × 10−8 (Dudbridge, Gusnanto 2008) and Bonferroni correction: 5 × 10−8(So, Sham 
2011).      
The aim of this study is to detect SNPs that are significantly associated with DN and or 
eGFR, considering Bonferroni correction, although no SNP showed significant 
association after correction for multiple testing; the top associated SNP was (rs1285582, 
𝜒2: 29.55, unadjusted p-value: 5.46 × 10−8, OR: 0.42) located on the long arm of 
chromosome X, the genomic inflation factor (λ: 1.03567), MAF: 0.14 and 0.27 in cases 
and controls respectively; its function consequence is the nc transcript variant, the utr 
variant 3 prime; the related gene is (NUP62CL) nucleoporin 62kDa C-terminal like 
(NCBI 2016). In single-point analysis, the OR compares individual SNP frequencies 
between cases and controls, OR with value greater than one supports that the SNP is 
causative for the trait under investigation and OR with value less than one indicates that 
the SNP is protective considering the disease status; since OR is less than 1, it would be 
interpreted that exposure to this SNP could be protective. The association analysis 
identified 14 SNPs with an unadjusted 𝑝 < 1 × 10−5 (table 8) associated with DN; of 
those, 6 SNPs are located on chromosome X, 2 SNPS are located on chromosome 6 and 2 
SNPs are located on chromosome 3 (table 8). Other significance levels are reported when 
using " − −𝑎𝑑𝑗𝑢𝑠𝑡" function in P-link (Purcell 2009, Purcell 2010) including false 
discovery rate (FDR); Sidak correction, i.e. 𝛼 = 1 − (1 − 0.05)1 𝑚⁄  where m is the 
number of independent tests and α is the significance level (So, Sham 2011); and non-
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parametric stepwise test recommended by Holm (Holm 1979, Dmitrienko, Wiens et al. 
2006).  
Table 8: Associated SNPs with DN and Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓 in AAs 
CHR SNP UNADJ GC BONF HOLM SIDAK_SS SIDAK_SD FDR_BH FDR_BY 
23 rs1285582 5.46E-08 9.23E-08 0.0427 0.0427 0.0418 0.0418 0.0427 0.6042 
23 rs1285715 2.54E-07 4.08E-07 0.1988 0.1988 0.1803 0.1803 0.09939 1 
17 rs9904264 1.29E-06 1.96E-06 1 1 0.635 0.635 0.2797 1 
4 rs4833161 1.59E-06 2.40E-06 1 1 0.7114 0.7114 0.2797 1 
13 rs7330933 1.79E-06 2.69E-06 1 1 0.7531 0.7531 0.2797 1 
23 rs2782219 2.98E-06 4.42E-06 1 1 0.9033 0.9033 0.292 1 
23 rs2528724 2.98E-06 4.42E-06 1 1 0.9033 0.9033 0.292 1 
23 rs2528720 2.98E-06 4.42E-06 1 1 0.9033 0.9033 0.292 1 
14 rs1951981 3.60E-06 5.29E-06 1 1 0.9402 0.9402 0.313 1 
6 rs9367077 4.70E-06 6.85E-06 1 1 0.9747 0.9747 0.3676 1 
6 rs7741325 6.49E-06 9.36E-06 1 1 0.9938 0.9938 0.4575 1 
3 rs1828671 8.84E-06 1.26E-05 1 1 0.999 0.999 0.4575 1 
3 rs17421075 8.84E-06 1.26E-05 1 1 0.999 0.999 0.4575 1 
23 rs5921139 9.50E-06 1.35E-05 1 1 0.9994 0.9994 0.4575 1 
CHR: Chromosome number, SNP: SNP identifier, UNADJ: Unadjusted asymptotic significance p-value, 
GC: Genomic-control corrected p-values, BONF: Bonferroni single-step adjusted p-values, HOLM: Holm 
(1970) step-down adjusted p-values, SIDAK_SS: Sidak single-step adjusted p-values, SIDAK_SD: Sidak 
step-down adjusted p-values, FDR_BH: Benjamini & Hochberg (1995) step-up FDR control, FDR_BY: 
Benjamini & Yekutieli (2001) step-up FDR control. 
II.6.1.2. Female/Male African Americans 
The population stratification has been investigated among females and males African 
Americans separately; the results are demonstrated in table 9, table 10, figure 2 and figure 
3. 
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Table 9: Permutation Test, IBS Differences among female AAs 
Between-group IBS (mean, SD) = 0.818024, 0.00336845 
In-group (2) IBS (mean, SD) = 0.818529, 0.00287222 
In-group (1) IBS (mean, SD) = 0.817551, 0.00370617 
Approximate proportion of variance between group = 0.00135679 
IBS group-difference empirical p-values 
No Description Empirical p-value 
T1 Case/control less similar 0.0115199 
T2 Case/control more similar 0.98849 
T3 Case/case less similar than control/control 0.98916 
T4 Case/case more similar than control/control 0.0108499 
T5 Case/case less similar 0.989 
T6 Case/case more similar 0.0110099 
T7 Control/control less similar 0.0104599 
T8 Control/control more similar 0.98955 
T9 Case/case less similar than case/control 0.98885 
T10 Case/case more similar than case/control 0.0111599 
T11 Control/control less similar than case/control 0.00944991 
T12 Control/control more similar than case/control 0.99056 
Between-group: case/control, group 1: control/control, group 2: case/case 
 
Figure 2: Multidimensional scaling plots in female AAs 
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Table 10: Permutation Test, IBS Differences among male AAs 
Between-group IBS (mean, SD) = 0.81796, 0.003327 
In-group (2) IBS (mean, SD) = 0.818153, 0.00302344 
In-group (1) IBS (mean, SD) = 0.817795, 0.00356257 
Approximate proportion of variance between group = 0.000629879 
IBS group-difference empirical p-values 
No Description Empirical p-value 
T1 Case/control less similar 0.275467 
T2 Case/control more similar 0.724543 
T3 Case/case less similar than control/control 0.710103 
T4 Case/case more similar than control/control 0.289907 
T5 Case/case less similar 0.715663 
T6 Case/case more similar 0.284347 
T7 Control/control less similar 0.309337 
T8 Control/control more similar 0.690673 
T9 Case/case less similar than case/control 0.719433 
T10 Case/case more similar than case/control 0.280577 
T11 Control/control less similar than case/control 0.743833 
T12 Control/control more similar than case/control 0.256177 
Between-group: case/control, group 1: control/control, group 2: case/case 
Figure 3: Multidimensional scaling plots in male AAs 
 
Genomic inflation factor (based on median chi-squared) or λ is 1.03136 and 1.01609 in 
female AAs and male AAs respectively; considering the tests, multidimensional plots and 
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genomic inflation factor it seems that there is not population stratification in these 
samples although the empirical p-values in males AAs are not significant.   
To determine SNP(s) that might be sex dependent, association tests were conducted on 
each sex separately; after correction for multiple testing, no SNP was significantly 
associated. The top associated SNP was (rs6705592, 𝜒2: 21.80, unadjusted p-value: 
3.02 × 10−6, OR: 2.16) an intron variant located on the SLC8A1 antisense RNA 1 
(SLC8A1-AS1) gene on the short arm of chromosome 2 (NCBI 2016), the genomic 
inflation factor (λ: 1.03136), MAF: 0.34 and 0.19 in cases and controls respectively in 
females; and (rs3857190, 𝜒2: 23.80, unadjusted p-value: 1.07 × 10−6, OR: 0.26) an 
intergenic variant located on the long arm of chromosome 4 (NCBI 2016), the genomic 
inflation factor (λ: 1.01609), MAF: 0.12 and 0.34 in cases and controls respectively in 
males. SNPs with unadjusted 𝑝 < 1 × 10−5 and are listed in table 11 and table 12. 
Table 11: Associated SNPs with DN and Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓in Female AAs 
CHR SNP UNADJ GC BONF HOLM SIDAK_SS SIDAK_SD FDR_BH FDR_BY 
2 rs6705592 3.02E-06 4.27E-06 1 1 0.9058 0.9058 0.6185 1 
22 rs2058119 3.50E-06 4.92E-06 1 1 0.9351 0.9351 0.6185 1 
21 rs858044 3.69E-06 5.18E-06 1 1 0.9443 0.9443 0.6185 1 
2 rs1541568 4.73E-06 6.60E-06 1 1 0.9753 0.9753 0.6185 1 
21 rs2406176 9.01E-06 1.23E-05 1 1 0.9991 0.9991 0.6185 1 
8 rs10090978 9.48E-06 1.30E-05 1 1 0.9994 0.9994 0.6185 1 
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Table 12: Associated SNPs with DN and Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓 in Male AAs 
CHR SNP UNADJ GC BONF HOLM SIDAK_SS SIDAK_SD FDR_BH FDR_BY 
4 rs3857190 1.07E-06 1.30E-06 0.8353 0.8353 0.5663 0.5663 0.6324 1 
1 rs2786864 2.55E-06 3.06E-06 1 1 0.864 0.864 0.6324 1 
1 rs2744778 2.55E-06 3.06E-06 1 1 0.864 0.864 0.6324 1 
2 rs6437092 6.24E-06 7.39E-06 1 1 0.9924 0.9924 0.6324 1 
2 rs6437089 6.24E-06 7.39E-06 1 1 0.9924 0.9924 0.6324 1 
2 rs6437097 6.24E-06 7.39E-06 1 1 0.9924 0.9924 0.6324 1 
2 rs4284824 6.24E-06 7.39E-06 1 1 0.9924 0.9924 0.6324 1 
5 rs12656464 6.46E-06 7.65E-06 1 1 0.9936 0.9936 0.6324 1 
9 rs967294 8.51E-06 1.00E-05 1 1 0.9987 0.9987 0.6658 1 
3 rs1020042 8.51E-06 1.00E-05 1 1 0.9987 0.9987 0.6658 1 
 
II.6.1.3. European Americans 
The number of SNPs and individuals before and after filtering are summarized in table 
13. 
Table 13: The Results of Quality Control Metrics in EAs 
 Before Filtering After Filtering 
Number of SNPs 932534 676504 
Number of Cases 339 187 
Number of Controls 424 253 
Number of Males 349 193 
Number of Females 414 247 
 
Permutation test for between group IBS differences was conducted, and the result is 
described in the table 14. The multidimensional scaling plots are illustrated in figure 4. 
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Table 14: Permutation Test, IBS Differences among EAs 
Between-group IBS (mean, SD) = 0.873521, 0.00169252 
In-group (2) IBS (mean, SD) = 0.87357, 0.00146153 
In-group (1) IBS (mean, SD) = 0.873474, 0.0018746 
Approximate proportion of variance between group = 1.43504e-005 
IBS group-difference empirical p-values 
No Description Empirical p-value 
T1 Case/control less similar 0.639104 
T2 Case/control more similar 0.360906 
T3 Case/case less similar than control/control 0.656983 
T4 Case/case more similar than control/control 0.343027 
T5 Case/case less similar 0.659943 
T6 Case/case more similar 0.340067 
T7 Control/control less similar 0.345317 
T8 Control/control more similar 0.654693 
T9 Case/case less similar than case/control 0.671813 
T10 Case/case more similar than case/control 0.328197 
T11 Control/control less similar than case/control 0.348577 
T12 Control/control more similar than case/control 0.651433 
Between-group: case/control, group 1: control/control, group 2: case/case 
 
Figure 4: Multidimensional scaling plots in EAs 
 
None of the empirical p-values of IBS group-difference is significant although the 
approximate proportion of variance between groups equals to 1.43504e-005. The sample 
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shows, almost, one cluster in multidimensional plots, and the genomic inflation factor (λ) 
approximates to 1.01138. Therefore, it could be concluded that population stratification 
does not exist.    
The top associated SNP was (rs4774390,𝜒2: 27.67, unadjusted p-value:1.44 × 10−7, OR: 
0.47), an intron variant located in RAR related orphan receptor A (RORA) gene on the 
long arm of chromosome 15 (NCBI 2016), the genomic inflation factor (λ: 1.01138), 
MAF: 0.28 and 0.46 in cases and controls respectively; the association was not 
significant after correction for multiple testing; SNPs with unadjusted 𝑝 < 1 × 10−5 are 
listed in the table 15. 
Table 15: Associated SNPs with DN and Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓in EAs 
CHR SNP UNADJ GC BONF HOLM SIDAK_SS SIDAK_SD FDR_BH FDR_BY 
15 rs4774390 1.44E-07 1.69E-07 0.09735 0.09735 0.09276 0.09276 0.09735 1 
5 rs6884502 6.22E-07 7.19E-07 0.4207 0.4207 0.3434 0.3434 0.2103 1 
1 rs4532841 3.09E-06 3.51E-06 1 1 0.8762 0.8762 0.6963 1 
14 rs11620655 4.16E-06 4.71E-06 1 1 0.9399 0.9399 0.7031 1 
23 rs5905843 5.92E-06 6.68E-06 1 1 0.9818 0.9818 0.8009 1 
8 rs919659 7.15E-06 8.05E-06 1 1 0.9921 0.9921 0.8059 1 
 
II.6.1.4. Female/Male European Americans 
Population stratification was verified, the results are summarized in table 16, table 17, 
figure 5, and figure 6.  
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Table 16: Permutation Test, IBS Differences in female EAs 
Between-group IBS (mean, SD) = 0.873696, 0.001642 
In-group (2) IBS (mean, SD) = 0.873947, 0.00103401 
In-group (1) IBS (mean, SD) = 0.87344, 0.00205764 
Approximate proportion of variance between group = 0.00118486 
IBS group-difference empirical p-values 
No Description Empirical p-value 
T1 Case/control less similar 0.95383 
T2 Case/control more similar 0.0461795 
T3 Case/case less similar than control/control 0.949571 
T4 Case/case more similar than control/control 0.0504395 
T5 Case/case less similar 0.947681 
T6 Case/case more similar 0.0523295 
T7 Control/control less similar 0.0494195 
T8 Control/control more similar 0.95059 
T9 Case/case less similar than case/control 0.930731 
T10 Case/case more similar than case/control 0.0692793 
T11 Control/control less similar than case/control 0.0485195 
T12 Control/control more similar than case/control 0.95149 
Between-group: case/control, group 1: control/control, group 2: case/case 
 
Figure 5: Multidimensional scaling plots in female EAs 
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Table 17: Permutation Test, IBS Differences in male EAs 
Between-group IBS (mean, SD) = 0.873362, 0.00166999 
In-group (2) IBS (mean, SD) = 0.873231, 0.00168415 
In-group (1) IBS (mean, SD) = 0.873538, 0.00153057 
Approximate proportion of variance between group = 0.000104152 
IBS group-difference empirical p-values 
No Description Empirical p-value 
T1 Case/control less similar 0.0164398 
T2 Case/control more similar 0.98357 
T3 Case/case less similar than control/control 0.170078 
T4 Case/case more similar than control/control 0.829932 
T5 Case/case less similar 0.188898 
T6 Case/case more similar 0.811112 
T7 Control/control less similar 0.846402 
T8 Control/control more similar 0.153608 
T9 Case/case less similar than case/control 0.237398 
T10 Case/case more similar than case/control 0.762612 
T11 Control/control less similar than case/control 0.870571 
T12 Control/control more similar than case/control 0.129439 
Between-group: case/control, group 1: control/control, group 2: case/case 
 
Figure 6: Multidimensional scaling plots in male EAs 
 
Genomic inflation factor (λ) was assessed, which is reported to be 1.00 and 1.04522 in 
female EAs and male EAs respectively. Although male EAs show more scattering 
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compared to female EAs in multidimensional, considering the λ values, it does not seem 
that population stratification exists in these samples.    
To investigate sex dependent SNP(s), association tests were conducted on each sex 
separately; after correction for multiple testing, no SNP was significantly associated. The 
top associated SNPs were (rs2069347, 𝜒2: 24.98, unadjusted p-value:5.79 × 10−7, OR: 
2.60) an intron variant located on cyclin G1 (CCNG1) gene on the long arm of 
chromosome 5 (NCBI 2016), the genomic inflation factor (λ: 1.00), MAF: 0.64 and 0.41 
in cases and controls respectively in female EAs; and (rs1239911 and rs1239908, 𝜒2: 
26.89, unadjusted p-value:2.16 × 10−7, OR: 3.04) two intron variants located on the long 
intergenic non-protein coding RNA 1481 (LINC01481) gene on the long arm of 
chromosome 12 (NCBI 2016), the genomic inflation factor (λ: 1.04522), MAF: 0.53 and 
0.27 in cases and controls in male EAs. SNPs with unadjusted 𝑝 < 1 × 10−5 are listed in 
table 18 and table 19. 
Table 18: Associated SNPs with DN and Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓 in female EAs 
CHR SNP UNADJ GC BONF HOLM SIDAK_SS SIDAK_SD FDR_BH FDR_BY 
5 rs2069347 5.79E-07 5.79E-07 0.3918 0.3918 0.3241 0.3241 0.2084 1 
2 rs4675095 6.57E-07 6.57E-07 0.4447 0.4447 0.359 0.359 0.2084 1 
5 rs3756648 1.05E-06 1.05E-06 0.7108 0.7108 0.5088 0.5088 0.2084 1 
8 rs4535723 1.23E-06 1.23E-06 0.8335 0.8335 0.5655 0.5655 0.2084 1 
8 rs4531033 4.85E-06 4.85E-06 1 1 0.9625 0.9625 0.6565 1 
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Table 19: Associated SNPs with DN and Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓 in male EAs 
CHR SNP UNADJ GC BONF HOLM SIDAK_SS SIDAK_SD FDR_BH FDR_BY 
12 rs1239911 2.16E-07 3.94E-07 0.146 0.146 0.1358 0.1358 0.073 1 
12 rs1239908 2.16E-07 3.94E-07 0.146 0.146 0.1358 0.1358 0.073 1 
2 rs10932732 3.00E-06 4.91E-06 1 1 0.8686 0.8686 0.5323 1 
2 rs6743834 5.03E-06 8.05E-06 1 1 0.9666 0.9666 0.5323 1 
8 rs2118063 5.30E-06 8.47E-06 1 1 0.9723 0.9723 0.5323 1 
8 rs1526347 7.01E-06 1.11E-05 1 1 0.9913 0.9913 0.5323 1 
12 rs11178059 7.22E-06 1.14E-05 1 1 0.9925 0.9925 0.5323 1 
8 rs2693804 8.15E-06 1.28E-05 1 1 0.996 0.996 0.5323 1 
8 rs750342 8.63E-06 1.35E-05 1 1 0.9971 0.9971 0.5323 1 
8 rs750343 8.66E-06 1.36E-05 1 1 0.9971 0.9971 0.5323 1 
8 rs2704255 8.66E-06 1.36E-05 1 1 0.9971 0.9971 0.5323 1 
  
II.6.1.5. Mexican Americans 
The number of SNPs and individuals before and after filtering are summarized in table 
20. 
Table 20: The Results of Quality Control Metrics in MAs 
 Before Filtering After Filtering 
Number of SNPs 932534 683140 
Number of Cases 534 81 
Number of Controls 466 38 
Number of Males 397 56 
Number of Females 603 63 
 
Population stratification was investigated and the results are presented in table 21 and 
figure 7.  
  
54 
 
Table 21: Permutation Test, IBS Differences in MAs 
Between-group IBS (mean, SD) = 0.87321, 0.00294932 
In-group (2) IBS (mean, SD) = 0.873021, 0.00298606 
In-group (1) IBS (mean, SD) = 0.873323, 0.0028272 
Approximate proportion of variance between group = 0.000512768 
IBS group-difference empirical p-values 
No Description Empirical p-value 
T1 Case/control less similar 0.698663 
T2 Case/control more similar 0.301347 
T3 Case/case less similar than control/control 0.331847 
T4 Case/case more similar than control/control 0.668163 
T5 Case/case less similar 0.324377 
T6 Case/case more similar 0.675633 
T7 Control/control less similar 0.651613 
T8 Control/control more similar 0.348397 
T9 Case/case less similar than case/control 0.316237 
T10 Case/case more similar than case/control 0.683773 
T11 Control/control less similar than case/control 0.0607294 
T12 Control/control more similar than case/control 0.939281 
Between-group: case/control, group 1: control/control, group 2: case/case 
 
Figure 7: Multidimensional scaling plots in MAs 
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The genomic inflation factor (λ) is equivalent to 1.02805; considering the λ value and one 
cluster illustrated in multidimensional scaling plot, it could be concluded that the sample 
does not include population stratification.  
The top associated SNP was (rs17067207, 𝜒2: 23.42, unadjusted p-value: 1.30 × 10−6, 
OR: 0.20), the genomic inflation factor (λ: 1.02805), MAF: 0.10 and 0.37 in cases and 
controls respectively. This SNP is an intergenic variant between RP11-67M9.1 and CTB-
7E3.1 genes located on the long arm of the chromosome 5 (NCBI 2016); the association 
was not significant after correction for multiple testing. SNPs with unadjusted 𝑝 < 1 ×
10−5 in this group are listed in the table 22. 
Table 22: SNPs Associated with DN and Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓in MAs 
CHR  SNP  UNADJ  GC  BONF  HOLM  SIDAK_SS  SIDAK_SD  FDR_BH  FDR_BY  
5 rs17067207 1.30E-06 1.81E-06 0.8882 0.8882 0.5886 0.5886 0.2994 1 
5 rs10516017 1.97E-06 2.71E-06 1 1 0.7393 0.7393 0.2994 1 
5 rs2964303 2.16E-06 2.98E-06 1 1 0.772 0.772 0.2994 1 
10 rs190411 4.01E-06 5.43E-06 1 1 0.9353 0.9353 0.2994 1 
7 rs11977436 4.64E-06 6.26E-06 1 1 0.9581 0.9581 0.2994 1 
3 rs2222630 5.00E-06 6.73E-06 1 1 0.9672 0.9672 0.2994 1 
3 rs10511393 5.00E-06 6.73E-06 1 1 0.9672 0.9672 0.2994 1 
3 rs16830002a 5.00E-06 6.73E-06 1 1 0.9672 0.9672 0.2994 1 
3 rs16830002b 5.00E-06 6.73E-06 1 1 0.9672 0.9672 0.2994 1 
3 rs16830004 5.00E-06 6.73E-06 1 1 0.9672 0.9672 0.2994 1 
3 rs4407429 5.00E-06 6.73E-06 1 1 0.9672 0.9672 0.2994 1 
5 rs2161413 5.70E-06 7.64E-06 1 1 0.9796 0.9796 0.2994 1 
5 rs349608 5.70E-06 7.64E-06 1 1 0.9796 0.9796 0.2994 1 
3 rs6806039 8.62E-06 1.14E-05 1 1 0.9972 0.9972 0.3694 1 
3 rs4680068 8.62E-06 1.14E-05 1 1 0.9972 0.9972 0.3694 1 
5 rs2923173 8.65E-06 1.15E-05 1 1 0.9973 0.9973 0.3694 1 
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II.6.1.6. Female/Male Mexican Americans 
Population stratification was assessed and the results are reported in the table 23, table 
24, figure 8 and figure 9.  
Table 23: Permutation Test, IBS Differences in female MAs 
Between-group IBS (mean, SD) = 0.87255, 0.00274349 
In-group (2) IBS (mean, SD) = 0.872487, 0.00318981 
In-group (1) IBS (mean, SD) = 0.872496, 0.00216365 
Approximate proportion of variance between group = 0.000112904 
IBS group-difference empirical p-values 
No Description Empirical p-value 
T1 Case/control less similar 0.572214 
T2 Case/control more similar 0.427796 
T3 Case/case less similar than control/control 0.482315 
T4 Case/case more similar than control/control 0.517695 
T5 Case/case less similar 0.471855 
T6 Case/case more similar 0.528155 
T7 Control/control less similar 0.501555 
T8 Control/control more similar 0.498485 
T9 Case/case less similar than case/control 0.460255 
T10 Case/case more similar than case/control 0.539755 
T11 Control/control less similar than case/control 0.328897 
T12 Control/control more similar than case/control 0.671113 
Between-group: case/control, group 1: control/control, group 2: case/case 
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Figure 8: Multidimensional scaling plots in female MAs 
 
Table 24: Permutation Test, IBS Differences in male MAs 
Between-group IBS (mean, SD) = 0.874189, 0.00316636 
In-group (2) IBS (mean, SD) = 0.873506, 0.00267958 
In-group (1) IBS (mean, SD) = 0.874757, 0.00357518 
Approximate proportion of variance between group = 0.00873541 
IBS group-difference empirical p-values 
No Description Empirical p-value 
T1 Case/control less similar 0.870051 
T2 Case/control more similar 0.129959 
T3 Case/case less similar than control/control 0.146329 
T4 Case/case more similar than control/control 0.853681 
T5 Case/case less similar 0.140839 
T6 Case/case more similar 0.859171 
T7 Control/control less similar 0.837142 
T8 Control/control more similar 0.162868 
T9 Case/case less similar than case/control 0.136329 
T10 Case/case more similar than case/control 0.863681 
T11 Control/control less similar than case/control 0.099259 
T12 Control/control more similar than case/control 0.900751 
Between-group: case/control, group 1: control/control, group 2: case/case 
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Figure 9: Multidimensional scaling plots in male MAs 
 
The genomic inflation factor (λ) equals to 1.02048 and 1.00251 in female and male MAs 
respectively. The λ value and clustering are in the favor of no population stratification in 
the samples although the number of individuals included in the analyses reduced 
considerably after constraining quality control metrics.  
To discover SNP(s) that might be sex dependent, association tests were conducted on 
each sex separately; after correction for multiple testing, no SNP was significantly 
associated with DN. The top associated SNPs were (rs2923173,𝜒2: 19.00, unadjusted p-
value: 1.31 ×  10−5, OR: 0.13), which is an intergenic variant between RP11-67M9.1 
and CTB-7E3.1 genes located on the long arm of the chromosome 5 (NCBI 2016), the 
genomic inflation factor (λ: 1.02048), MAF: 0.08 and 0.40 in cases and controls 
respectively in females; and (rs1106228,𝜒2: 24.74, unadjusted p-value: 6.55× 10−7, OR: 
0.03) an intergenic variant located on the long arm of the chromosome 9 between RP11-
343J18.2 and RP11-343J18.1 genes (Ensembl 2016), the genomic inflation factor (λ: 
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1.00251), MAF: 0.01 and 0.32 in cases and controls respectively in males. Only, one SNP 
in male MAs was detected with unadjusted 𝑝 < 1 × 10−5 which is listed in table 25. 
Table 25: SNP with Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓Associated with DN in male MAs 
CHR  SNP  UNADJ  GC  BONF  HOLM  SIDAK_SS  SIDAK_SD  FDR_BH  FDR_BY  
3 Rs1106228  6.55E-07 6.77E-07 0.4476 0.4476 0.3608 0.3608 0.4476 1 
 
The top associated SNPs with DN (unadjusted 𝑝 < 1 × 10−5) in each ethnic group, in 
this study, are listed in the table 26 although no SNP reached Bonferroni significance 
level. 
Table 26: Top Associated SNPs with DN in AAs, EAs and MAs 
Population  SNP  Variant  CHR  Position 
(Mb)  
Gene/Nearest gene(s)  
African Americans       
            All together  rs1285582  nc transcript variant,utr variant 3 
prime  
Xq  107.1 NUP62CL  
            Females  rs6705592  intron variant  2p  40.0 SLC8A1-AS1 
            Males  rs3857190  intergenic variant  4q  7.1 FLJ36777, SORCS2  
European 
Americans  
     
            All together  rs4774390  intron variant  15q  61.2 RORA  
            Females  rs2069347  intron variant  5q  163.4 CCNG1  
            Males  rs1239908  intron variant  12q  70.1 LINC01481  
Mexican Americans       
            All together  rs17067207  Intergenic variant 5q 166.6 RP11-67M9.1, CTB-7E3.1  
            Females  rs2923173  intergenic variant  5q 116.5 RP11-67M9.1, CTB-7E3.1 
            Males  rs1106228  intergenic variant  9q  126.2 RP11-343J18.2, RP11-343J18.1 
 
II.6.2. Genome-wide association scans for single SNPs associated with glomerular 
filtration rate (GFR) in T2D - FIND study: 
To be able to detect association with a quantitative outcome variable (i.e. GFR value), the 
values measured as laboratory eGFR provided in the phenotypic files have been used in a 
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linear regression model for further analyses; Bonferroni correction is considered as 
significance level. 
II.6.2.1. African Americans 
The top associated SNP with eGFR value was rs1285582 (unadjusted p-value: 9.97 ×
10−8, β: 14.07; β indicates regression coefficient, and p-value is asymptotic significance 
value for coefficient); nc transcript variant, utr variant 3 prime located on the nucleoporin 
62kDa C-terminal like (NUP62CL) gene located on the long arm of chromosome X 
(NCBI 2016). The results of the analysis of this SNP and those with p-value < 1  
are summarized in table 27. 
Table 27: SNPs with Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓Associated with eGFR in AAs 
CHR  SNP  UNADJ  GC  BONF  HOLM  SIDAK_SS  SIDAK_SD  FDR_BH  FDR_BY  
23 rs1285582 9.97E-08 1.10E-07 0.07801 0.07801 0.07505 0.07505 0.07801 1 
23 rs1285715 9.25E-07 1.01E-06 0.7242 0.7242 0.5153 0.5153 0.3621 1 
23 rs12559704 2.22E-06 2.40E-06 1 1 0.8239 0.8239 0.4415 1 
9 rs7031414 2.79E-06 3.01E-06 1 1 0.8871 0.8871 0.4415 1 
4 rs4833161 3.51E-06 3.79E-06 1 1 0.9359 0.9359 0.4415 1 
3 rs9843448 4.23E-06 4.56E-06 1 1 0.9634 0.9634 0.4415 1 
10 rs11011417 5.73E-06 6.16E-06 1 1 0.9887 0.9887 0.4415 1 
10 rs11817782 6.20E-06 6.67E-06 1 1 0.9922 0.9922 0.4415 1 
10 rs11011437 6.20E-06 6.67E-06 1 1 0.9922 0.9922 0.4415 1 
10 rs11011415 6.20E-06 6.67E-06 1 1 0.9922 0.9922 0.4415 1 
10 rs12267847 6.20E-06 6.67E-06 1 1 0.9922 0.9922 0.4415 1 
10 rs11011299 8.41E-06 9.03E-06 1 1 0.9986 0.9986 0.4887 1 
6 rs4413625 8.69E-06 9.32E-06 1 1 0.9989 0.9989 0.4887 1 
12 rs7970296 8.74E-06 9.38E-06 1 1 0.9989 0.9989 0.4887 1 
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II.6.2.2. Sex-specific association with GFR in African Americans 
To identify potential SNPs that their expression might be sex dependent, each sex was 
evaluated separately and the results for those SNPs with unadjusted p-value < 1 × 10−5  
are presented in table 28 and table 29. Although no SNP was significantly associated with 
eGFR value after correction for multiple testing (Bonferroni method), the top associated 
one was rs17820651 with unadjusted p-value: 3.57 × 10−6, a downstream gene variant 
located on the sulfotransferase family 1C member 3 (SULT1C3) gene on the long arm of 
the chromosome 2, and rs243294 with unadjusted p-value:9.81 × 10−7, an intron variant 
on the neuronal PAS domain protein 3 (NPAS3) gene located on the long arm of 
chromosome 14 in females and males respectively. 
Table 28: SNPs Associated with eGFR/ Female AAs with Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓  
CHR  SNP  UNADJ  GC  BONF  HOLM  SIDAK_SS  SIDAK_SD  FDR_BH  FDR_BY  
2 rs17820651 3.57E-06 3.76E-06 1 1 0.9389 0.9389 0.4927 1 
9 rs1759414 5.55E-06 5.83E-06 1 1 0.987 0.987 0.4927 1 
10 rs11011417 6.56E-06 6.89E-06 1 1 0.9941 0.9941 0.4927 1 
22 rs16998591 6.93E-06 7.28E-06 1 1 0.9956 0.9956 0.4927 1 
10 rs12267847 7.86E-06 8.25E-06 1 1 0.9979 0.9979 0.4927 1 
10 rs11011415 7.86E-06 8.25E-06 1 1 0.9979 0.9979 0.4927 1 
10 rs11817782 7.86E-06 8.25E-06 1 1 0.9979 0.9979 0.4927 1 
10 rs11011299 7.86E-06 8.25E-06 1 1 0.9979 0.9979 0.4927 1 
10 rs11011437 7.86E-06 8.25E-06 1 1 0.9979 0.9979 0.4927 1 
8 rs318873 8.16E-06 8.56E-06 1 1 0.9983 0.9983 0.4927 1 
1 rs12117655 8.31E-06 8.72E-06 1 1 0.9985 0.9985 0.4927 1 
23 rs9887370 8.99E-06 9.43E-06 1 1 0.9991 0.9991 0.4927 1 
10 rs12266900 9.26E-06 9.71E-06 1 1 0.9993 0.9993 0.4927 1 
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Table 29: SNPs Associated with eGFR/ Male AAs with Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓  
CHR  SNP  UNADJ  GC  BONF  HOLM  SIDAK_SS  SIDAK_SD  FDR_BH  FDR_BY  
14 rs243294 9.81E-07 1.03E-06 0.7681 0.7681 0.5361 0.5361 0.4479 1 
12 rs28739424 1.17E-06 1.22E-06 0.9123 0.9123 0.5984 0.5984 0.4479 1 
4 rs3857190 1.72E-06 1.79E-06 1 1 0.7391 0.7391 0.4479 1 
20 rs6035372 5.02E-06 5.22E-06 1 1 0.9803 0.9803 0.5385 1 
2 rs4284824 5.50E-06 5.72E-06 1 1 0.9865 0.9865 0.5385 1 
2 rs6437089 5.50E-06 5.72E-06 1 1 0.9865 0.9865 0.5385 1 
2 rs6437092 5.50E-06 5.72E-06 1 1 0.9865 0.9865 0.5385 1 
2 rs6437097 5.50E-06 5.72E-06 1 1 0.9865 0.9865 0.5385 1 
2 rs4973069 7.44E-06 7.72E-06 1 1 0.997 0.997 0.5702 1 
2 rs17027920 7.91E-06 8.21E-06 1 1 0.9979 0.9979 0.5702 1 
3 rs13322971 8.01E-06 8.32E-06 1 1 0.9981 0.9981 0.5702 1 
 
II.6.2.3. European Americans 
When both sexes in European Americans group were analyzed together, the top 
associated one was rs4774390, unadjusted p-value: 3.64 × 10−7, an intron variant 
located on the RAR related orphan receptor A (RORA) gene on the long arm of 
chromosome 15; table 30 listed those SNPs with 𝑝 < 1 × 10−5 although no SNP was 
significantly associated after Bonferroni correction for multiple testing (NCBI 2016, 
Ensembl 2016). 
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Table 30: SNPs Associated with eGFR in EAs with Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓    
CHR  SNP  UNADJ  GC  BONF  HOLM  SIDAK_SS  SIDAK_SD  FDR_BH  FDR_BY  
15 rs4774390 3.64E-07 3.73E-07 0.2461 0.2461 0.2182 0.2182 0.1981 1 
3 rs1373814 9.29E-07 9.50E-07 0.6287 0.6287 0.4667 0.4667 0.1981 1 
3 rs1373813 9.29E-07 9.50E-07 0.6287 0.6287 0.4667 0.4667 0.1981 1 
3 rs2120925 1.23E-06 1.26E-06 0.8316 0.8316 0.5647 0.5647 0.1981 1 
3 rs9874828 1.48E-06 1.51E-06 1 1 0.6327 0.6327 0.1981 1 
3 rs11715833 1.76E-06 1.79E-06 1 1 0.6954 0.6954 0.1981 1 
15 rs930847 2.08E-06 2.12E-06 1 1 0.7545 0.7545 0.2006 1 
3 rs10935157 3.21E-06 3.27E-06 1 1 0.8858 0.8858 0.2411 1 
3 rs9877871 3.21E-06 3.27E-06 1 1 0.8858 0.8858 0.2411 1 
 
II.6.2.4. Sex Specific European Americans 
The SNPs associated with eGFR value with unadjusted p-value less than 1 × 10−5 in 
female European Americans are listed in the table 31; top associated one is rs4675095, an 
intron variant located on the insulin receptor substrate 1 (IRS1) gene on the long arm of 
chromosome 2 (NCBI 2016, Ensembl 2016). 
Table 31: SNPs Associated with eGFR and Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓 in EA Females 
CHR  SNP  UNADJ  GC  BONF  HOLM  SIDAK_SS  SIDAK_SD  FDR_BH  FDR_BY  
2 rs4675095 5.62E-06 5.91E-06 1 1 0.9777 0.9777 0.9011 1 
15 rs4774390 5.66E-06 5.95E-06 1 1 0.9782 0.9782 0.9011 1 
5 rs2069347 8.65E-06 9.08E-06 1 1 0.9971 0.9971 0.9011 1 
 
In male European Americans, SNPs associated with GFR having unadjusted p-value less 
than 1 × 10−5, are listed in Table 32; no SNP was significantly associated after 
Bonferroni correction for multiple testing. The top associated one was rs2118063, p-
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value: 7.46 × 10−7; an intergenic variant between syndecan 2 (SDC2) and 
carboxypeptidase Q (CPQ) genes located on the long arm of chromosome 8.  
Table 32: SNPs Associated with eGFR in Male EAs, Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓 
CHR  SNP  UNADJ  GC  BONF  HOLM  SIDAK_SS  SIDAK_SD  FDR_BH  FDR_BY  
8 rs2118063 7.46E-07 9.94E-07 0.5049 0.5049 0.3964 0.3964 0.183 1 
8 rs10086882 1.02E-06 1.34E-06 0.6864 0.6864 0.4966 0.4966 0.183 1 
9 rs10781011 1.04E-06 1.37E-06 0.6999 0.6999 0.5034 0.5034 0.183 1 
17 rs7226040 1.83E-06 2.39E-06 1 1 0.7095 0.7095 0.183 1 
8 rs2704255 1.90E-06 2.48E-06 1 1 0.723 0.723 0.183 1 
8 rs750343 1.90E-06 2.48E-06 1 1 0.723 0.723 0.183 1 
8 rs750342 2.03E-06 2.65E-06 1 1 0.7471 0.7471 0.183 1 
8 rs2018041 2.16E-06 2.82E-06 1 1 0.7687 0.7687 0.183 1 
21 rs2835611 7.77E-06 9.86E-06 1 1 0.9948 0.9948 0.5256 1 
21 rs2835583 7.77E-06 9.86E-06 1 1 0.9948 0.9948 0.5256 1 
 
II.6.2.5. Mexican Americans  
The association test in Mexican Americans doesn't detect any SNPs significantly 
associated with GFR. The SNPs with unadjusted p value less than 1 × 10−5 are 
summarized in table 33, 34 and 35. The top associated one, when both sexes were 
included, was rs6806039, an intron variant on the clarin 1 (CLRN1) gene with p-value: 
1.83 × 10−8 located on the long arm of chromosome 3(Ensembl 2016, NCBI 2016).  
II.6.2.6. Sex Specific Mexican Americans 
The primary sex specific analysis showed that seven SNPs achieved unadjusted p-value 
less than 1 × 10−5 in females; the top associated SNP in this group was rs10949778 with 
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p-value: 9.11 × 10−8, a downstream gene variant located on the long arm chromosome 
7; in male Mexican Americans, twelve SNPs were associated with GFR with p-value<
1 × 10−5; the top one was rs4904196, an intergenic variant located on the long arm of 
chromosome 14 with unadjusted p-value:3.75 × 10−7.          
Table 33: SNPs with Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓Associated with eGFR in MAs 
CHR  SNP  UNADJ  GC  BONF  HOLM  SIDAK_SS  SIDAK_SD  FDR_BH  FDR_BY  
3 rs6806039 1.83E-08 1.83E-08 0.01252 0.01252 0.01244 0.01244 0.006261 0.08772 
3 rs4680068 1.83E-08 1.83E-08 0.01252 0.01252 0.01244 0.01244 0.006261 0.08772 
6 rs2235406 1.75E-06 1.75E-06 1 1 0.6982 0.6982 0.2886 1 
5 rs9313277 4.29E-06 4.29E-06 1 1 0.9465 0.9465 0.2886 1 
5 rs12233967 4.29E-06 4.29E-06 1 1 0.9465 0.9465 0.2886 1 
7 rs11769954 4.72E-06 4.72E-06 1 1 0.9602 0.9602 0.2886 1 
10 rs11015025 5.72E-06 5.72E-06 1 1 0.9799 0.9799 0.2886 1 
3 rs2222630 5.81E-06 5.81E-06 1 1 0.981 0.981 0.2886 1 
3 rs4407429 5.81E-06 5.81E-06 1 1 0.981 0.981 0.2886 1 
3 rs10511393 5.81E-06 5.81E-06 1 1 0.981 0.981 0.2886 1 
3 rs16830002a 5.81E-06 5.81E-06 1 1 0.981 0.981 0.2886 1 
3 rs16830002b 5.81E-06 5.81E-06 1 1 0.981 0.981 0.2886 1 
3 rs16830004 5.81E-06 5.81E-06 1 1 0.981 0.981 0.2886 1 
5 rs12187731 6.24E-06 6.24E-06 1 1 0.9859 0.9859 0.2886 1 
6 rs2235412 6.34E-06 6.34E-06 1 1 0.9868 0.9868 0.2886 1 
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Table 34: SNPs Associated with eGFR, Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓 in Female MAs 
CHR  SNP  UNADJ  GC  BONF  HOLM  SIDAK_SS  SIDAK_SD  FDR_BH  FDR_BY  
7 rs10949778 9.11E-08 9.11E-08 0.06219 0.06219 0.0603 0.0603 0.06219 0.8714 
7 rs10272697 7.06E-07 7.06E-07 0.4822 0.4822 0.3826 0.3826 0.2411 1 
20 rs17789761 3.06E-06 3.06E-06 1 1 0.8759 0.8759 0.5331 1 
14 rs2152977 3.61E-06 3.61E-06 1 1 0.915 0.915 0.5331 1 
7 rs7785498 3.90E-06 3.90E-06 1 1 0.9304 0.9304 0.5331 1 
7 rs41434053 4.76E-06 4.76E-06 1 1 0.9612 0.9612 0.5417 1 
3 rs7643629 7.51E-06 7.51E-06 1 1 0.9941 0.9941 0.6575 1 
Table 35: SNPs Associated with eGFR in Male MAs, Unadjusted 𝒑 < 𝟏 × 𝟏𝟎−𝟓  
CHR  SNP  UNADJ  GC  BONF  HOLM  SIDAK_SS  SIDAK_SD  FDR_BH  FDR_BY  
14 rs4904196 3.75E-07 3.75E-07 0.2565 0.2565 0.2262 0.2262 0.2196 1 
1 rs12409665 7.50E-07 7.50E-07 0.5123 0.5123 0.4009 0.4009 0.2196 1 
8 rs7008234 9.65E-07 9.65E-07 0.6588 0.6588 0.4825 0.4825 0.2196 1 
3 rs10934434 2.21E-06 2.21E-06 1 1 0.7797 0.7797 0.3392 1 
3 rs13433683 3.67E-06 3.67E-06 1 1 0.9182 0.9182 0.3392 1 
3 rs1872239 3.67E-06 3.67E-06 1 1 0.9182 0.9182 0.3392 1 
3 rs13314357 3.67E-06 3.67E-06 1 1 0.9182 0.9182 0.3392 1 
8 rs17667096 3.97E-06 3.97E-06 1 1 0.9337 0.9337 0.3392 1 
6 rs932600 6.43E-06 6.43E-06 1 1 0.9876 0.9876 0.4447 1 
3 rs6790274 6.70E-06 6.70E-06 1 1 0.9897 0.9897 0.4447 1 
15 rs2243453 9.29E-06 9.29E-06 1 1 0.9982 0.9982 0.4447 1 
13 rs17635528 9.37E-06 9.37E-06 1 1 0.9983 0.9983 0.4447 1 
 
The top associated SNPs with eGFR (unadjusted 𝑝 < 1 × 10−5) in each ethnic group, in 
this study, are listed in the table 36 although no SNP reached Bonferroni significance 
level.   
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Table 36: Top Associated SNPs with eGFR in AAs, EAs and MAs 
Population  SNP  Variant  CHR  Position (Mb)  Gene/Nearest gene(s)  
African Americans       
            All together  rs1285582  nc transcript variant,utr variant 3  Xq  107.1 NUP62CL  
            Females  rs17820651  Downstream gene  variant 2q  108.3 SULT1C3, SULT1C2  
            Males  rs243294 Intron variant 14q 33.3 NPAS3 
European Americans      
            All together  rs4774390 Intron variant 15q  61.2 RORA 
            Females  rs4675095  intron variant  2q  226.8 IRS1  
            Males  rs2118063  intergenic variant  8q  96.6 SDC2, CPQ  
Mexican Americans       
            All together  rs4680068 intron variant  3q  150.9 CLRN1  
            Females  rs10949778 Downstream gene  variant 7q  155.4 AC008060.8  
            Males  rs4904196  Intergenic variant  14q  84.7 MTCYBP27, RNU6-976P  
II.6.3. Region Analyses 
Further analyses have been performed to identify potential regions that might be plausible 
for more investigation to detect an association with DN or variation in eGFR value that 
could not be found primarily by association tests conducted as genome-wide association. 
The SNPs that were found to be associated with DN or eGFR changes with unadjusted 
𝑝 − 𝑣𝑎𝑙𝑢𝑒 < 1 × 10−5 have been reassessed considering their position and p-values and 
will be discussed for each group. 
II.6.3.1. Assessing regions that might be associated with DN  
II.6.3.1.1. African Americans all together: 
rs1828671 and rs17421075 (table 8) are intron variants in the transmembrane protein 212 
(TMEM212) gene located on the long arm of chromosome 3 (NCBI 2016); previously, 
Ng & Hester reported that one SNP (i.e. rs6794092) which is located near TMEM212 
was associated with BMI values in African Americans (Ng, Hester et al. 2012). There are 
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evidences that TMEM212 is likely expressed in the brain, one SNP in this gene was 
determined to be significantly associated with the fusiform face area activation (Brown, 
Jensen et al. 2012). It was detected as one of the completely differentially regulated genes 
in response to hypoxia (Baghbani, Raoofian et al. 2013). It has been identified that 
TMEM212 is associated with blood pressure response to angiotensin II receptor blockers 
(Turner, Bailey et al. 2012); this gene was found to be, sex dependently, associated with 
reactivity variables of blood pressure (Nagel 2014).     
rs1285715 (table 8) is an utr variant 3 prime, associated with RNA binding motif protein 
41 (RBM41) gene located on the long arm of chromosome X (NCBI 2016); RBM41 
protein has been found to be associated with epidermal growth factor receptor (Tong, 
Taylor et al. 2008). 
rs1285582 (table 8) is a nc transcript variant, utr variant 3 prime, associated with 
nucleoporin 62kDa C-terminal like (NUP62CL) gene located on the long arm of 
chromosome X; the encoded protein is found in nuclear pore complexes (NCBI 2016). It 
was shown that in breast cancer the inactive X chromosome was epigenetically variable 
and adjacent genes could perform differently in a cancer environment; for example, while 
the NUP62CL remained silent in basal-like carcinoma cells, its near neighbor the nuclear 
transport factor 2-like export factor 2 (NXT2) gene displayed atypical transcription ( 
Chaligné, Popova et al. 2015). It was reported as one of the ciliary candidate genes due to 
its expression in cells with motile cilia and its function associated likely with such cells 
(Ivliev, 't Hoen et al. 2012). Both silencing and overexpression of syndecan-1 could alter 
NUP62CL expression (Szatmári, Mundt et al. 2012).    
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rs2528720, rs2528724 and rs2782219 (table 8) are Upstream gene variants associated 
with the sosondowah ankyrin repeat domain family member D (SOWAHD) gene located 
on the long arm of chromosome X (Ensembl 2016). In the human genome, SOWAHD is 
head-to-head linked to septin 6 (SEPT6) gene as the result of a single retroposition event 
(Maeso, Irimia et al. 2012). SEPT6 is required for cytokinesis (NCBI 2016).  
II.6.3.1.2. Female African Americans 
rs6705592 and rs1541568 (table 11) are intron variants associated with SLC8A1 
antisense RNA 1 (SLC8A1-AS1) gene located on the short arm of chromosome 2 (NCBI 
2016); this gene has been found to be related with allergic diseases (Ortiz, Barnes 2015). 
rs858044 and rs2406176 (table 11) are intron variants located on the potassium voltage-
gated channel subfamily J member 6 (KCNJ6) gene and transmembrane protease, serine 
15 (TMPRSS15) gene respectively; both are positioned on the long arm of chromosome 
21 (Ensembl 2016, NCBI 2016). It has been reported that performance of KCNJ6 gene, a 
putative ATP-sensitive K-channel subunit, is related to insulin release from βcells 
(Sakura, Bond et al. 1995); this gene is involved in pancreatic functions and has been 
found to be associated with T2D in Australian Aboriginal population (Anderson, Cordell 
et al. 2015). TMPRSS15 encodes an enzyme that is involved in the trypsin production 
(NCBI 2016); it is one of the taxol resistance gene candidates that its expression 
decreases by androgen receptor silencing (Sun, Huang et al. 2015). TMPRSS15 is related 
to hirschsprung disease, and its mutations may result in enterokinase deficiency (Liu, Lee 
et al. 2011).; it is one of the proteases that is expressed essentially in duodenum and 
jejunum in gastro intestinal tract by encoding enteropeptidase (Faller, Gautschi et al. 
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2014).; it has been shown that its expression is associated with human cytomegalovirus 
(HCMV) infection (Michaelis, Barth et al. 2012).                   
II.6.3.1.3. Male African Americans 
rs2744778 and rs2786864 (table 12) are intron variants associated with mannosidase, 
alpha, class 1C, a member 1 (MAN1C1) gene located on the short arm of chromosome 1 
(NCBI 2016). It has been reported that MAN1C1, by encoding a Golgi mannosidase, is 
associated with risk and size of the uterine leiomayomas in AAs (Aissani, Zhang et al. 
2015); it is also involved in the N-glycosylation pathway (Mkhikian, Grigorian et al. 
2011), and is related to preeclampsia (Moslehi, Mills et al. 2013). MAN1C1 expression is 
increased by T cell receptor signaling (Chen, Li et al. 2009).      
rs6437092, rs6437089, rs6437097 and rs4284824 (table 12) are intron variants on the 
inositol polyphosphate-5-phosphatase D (INPP5D) gene located on the long arm of 
chromosome 2 (Ensembl 2016); immune system malignancies and defects could be 
occurred due to mutations in this gene (NCBI 2016). This, biologically relevant, gene has 
been identified to be common in all multiple sclerosis phenotypes (Mahurkar, Moldovan 
et al. 2013). It has been found that INPP5D expression was enhanced in T2D (Marselli, 
Thorne et al. 2010). It has been shown that 5-ptases such as INPP5D are involved in 
macrophage phagocytosis regulation and haemopoietic cell proliferation (Ooms, Horan et 
al. 2009).   
II.6.3.1.4. Female European Americans 
rs2069347 and rs3756648 (table 18) are intron variants located on the CCNG1 gene and 
hyaluronan-mediated motility receptor (HMMR) gene respectively on the long arm of 
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chromosome 5 (Ensembl 2016). It has been reported that one SNP close to CCNG1 was 
significantly associated with systolic blood pressure (Org, Eyheramendy et al. 2009). 
HMMR is expressed in breast tissue and is involved in cell motility (NCBI 2016). Locus 
on HMMR was found to be associated with increased risk of breast cancer (Sinha, Gruber 
et al. 2008, Guo, Gao et al. 2011). Atypical expression of this gene was detected in 
primary and/or advanced prostate cancer (Willard, Koochekpour 2012). In animal 
models, it has been identified that HMMR is involved in adipogenesis regulation and 
diabetes pathogenesis (Liu, Bera et al. 2012, Yang, Gurung et al. 2010).     
rs4535723 and rs4531033 (table 18) are intergenic variants located between RP11-
381I15.1 gene and CTD-2501M5.1 gene on the long arm of chromosome 8 (Ensembl 
2016).    
II.6.3.1.5. Male European Americans 
rs1239911, rs1239908 and rs11178059 (table 19) are intron variants located in the long 
intergenic non-protein coding RNA 1481 (LINC01481) gene on the long arm of 
chromosome 12 (Ensembl 2016). rs1526347 and rs2693804 (table 19) are downstream 
gene variants close to ribosomal protein L23a pseudogene 54 (RPL23AP54) gene on the 
short arm of chromosome 8. rs2118063, rs750342, rs750343 and rs2704255 (table 19) are 
intergenic variants between syndecan 2 (SDC2) gene and carboxypeptidase Q (CPQ) 
gene, located on the long arm chromosome 8 (Ensembl 2016). It has been shown that 
SDC2 gene is involved in extracellular-receptor matrix interactions and cell adhesion 
molecules (Olsson, Volkov et al. 2014); its function is correlated with different growth 
factors pathways, inflammation, and lipid metabolism (Kelder, Verschuren et al. 2014, 
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Gotte 2003). SDC2 has been identified as one of the DNA methylation-based candidate 
genes for early detection of colorectal cancer (Mikeska, Craig 2014); it may also play 
role in whole-body energy metabolism regulation (De Luca, Klimentidis et al. 2010). In 
one study, interactions between offspring SNPs and maternal surgical (gastrointestinal 
bypass surgery for obesity) status was reviewed; CPQ was reported as one of the genes 
that showed significant interactions for multiple transcripts (Guénard, Lamontagne et al. 
2015). 
II.6.3.1.6. Mexican Americans 
rs2222630 (table 22) is an intron variant located on the CD80 molecule (CD80) gene, 
rs6806039 and rs4680068 (table 22) are intron variants in the clarin 1 (CLRN1) gene; 
five SNPs (rs4407429, rs10511393, rs16830002a, rs16830002b, and rs16830004; see 
table 22) which are intergenic variants between the CD80 and ADP-ribosylarginine 
hydrolase (ADPRH) genes, are located on the long arm of chromosome 3 (NCBI 2016, 
Ensembl 2016). rs17067207, rs10516017, rs2964303, rs2161413, rs349608 and 
rs2923173 (table 22) are intergenic variants located between CTB-7E3.1 gene and CTB-
63M22.1 gene on the long arm of chromosome 5 (Ensembl 2016).  
It has been reported that CD80 expression increases in obese humans, specifically on 
cells stimulating T cell proliferation (Deng, Lyon et al. 2013). Numbers of monocytes 
have been found to be increased in diabetics; greater expression of CD80 in the 
infiltrating monocytes implies a proinflammatory role for these cells (Espinoza-Jiménez, 
Peón et al. 2012, Bradshaw, Raddassi et al. 2009). It has been identified that CD80 gene 
expression enhanced in human keratinocytes in the presence of allergens and irritants 
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(Wakem, Burns et al. 2000). It has been described that CD80 plays role in the activation 
of T lymphocytes in hepatocarcinoma cells (Li, Zhu et al. 2006). A polymorphism of 
CD80 has been reported to be associated with lower risk of multiple sclerosis (Wagner, 
Sobczynski et al. 2015). 
CLRN1 function is associated with the development of the retina and its expression is 
increased in non-pigmented epithelium compared with pigmented epithelium (Janssen, 
Gorgels et al. 2012). Mutation in CLRN1 gene has been demonstrated to be associated 
with Usher’s syndrome and related to autosomal recessive retinitis pigmentosa (Khan, 
Kersten et al. 2011, Zhang, Sanders et al. 2014). It has been reported that this gene plays 
role in CD4
+
 T cell activation and Th2 differentiation (Techasintana, Davis et al. 2015). 
Mutations in this gene have been detected to be associated with higher prevalence of 
Usher syndrome in the Ashkenazi population (Ness, Ben-Yosef et al. 2003, Ben-Yosef, 
Ness et al. 2003, Guha, Rosenfeld et al. 2012). Considering its expression in inner ear, its 
function in the development of inner ear and actin organization, CLRN1 has been 
identified as one of the candidate genes that probably are involved in non-syndromic 
hearing loss phenotype (Accetturo, Creanza et al. 2010). 
ADPRH is expressed in the cytoplasm, and encodes an enzyme that is involved in 
removal of ADP-ribose from arginine residues (Laing, Unger et al. 2011). Its expression 
has been found to be increased in patients, with sleep disturbances, who self-reported 
improved sleep (Livingston, Rusch et al. 2015). This gene was one of the genes that were 
only differentially expressed in ankylosing spondylitis compared with systemic lupus 
erythematosus and systemic sclerosis (Assassi, Reveille et al. 2011)         
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II.6.3.2. Assessing regions that might be associated with eGFR values 
II.6.3.2.1. African Americans 
rs1285582 (table 27) is a 3 prime UTR variant in the NUP62CL gene, rs1285715 (table 
27) is a 3 prime UTR variant in the RBM41 gene and rs12559704 (table 27) is an intron 
variant of diaphanous related formin 2 (DIAPH2) gene, which all are located on the long 
arm of chromosome X; the latter one is related to ovary function (Ensembl 2016, NCBI 
2016). 
It has been identified that mutations in DIAPH2 are involved in infertility that are 
associated with hypergonadotrophic hypogonadism and premature ovarian failure (Bione, 
Sala et al. 1998, The Evian Annual Reproduction (EVAR) Workshop Group 2010, The 
Evian Annual Reproduction (EVAR) Workshop Group 2010 et al. 2011, Layman 2013); 
it is also linked to age related macular degeneration (Zheng, Joo et al. 2007, Tolppanen, 
Nevalainen et al. 2009).     
Six SNPs (table 27), located very close to centromere, on the short arm of chromosome 
10, have been identified to be associated with eGFR values: rs11011417 an intron variant 
in RP11-393J16.4 gene, rs11817782 and rs11011437 intron variants in zinc finger protein 
33A (ZNF33A) gene, rs11011415 intron variant in zinc finger protein 25 (ZNF25) gene, 
rs12267847 intergenic variant between zinc finger protein 33C, pseudogene (ZNF33CP) 
gene and ZNF25 gene, and rs11011299 an intergenic variant between MT-RNR2-like 7 
(MTRNR2L7) gene and RP11-258F22.1 gene (Ensembl 2016). 
Loci in ZNF33A and ZNF25 have been identified to be associated with bipolar disorder 
and type 2 diabetes (Ross 2011). Gene ontology analyses revealed that ZNF33A 
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expression was downregulated in the presence of diabetic nephropathy (Wanic, 
Krolewski et al. 2013); another study identified that its expression was upregulated in the 
patients with gastroesophageal reflux disease who stopped proton pump inhibitor 
treatment (De Vries, Ter Linde et al. 2009). It has been reported that its expression could 
be sex dependent (Maher, Fu et al. 2009). ZNF25 belongs to one of the two related ZNF 
gene clusters in pericentromeric region of chromosome 10; these two clusters are located 
opposite to each other around the centromere that could be occurred as the result of gene 
duplication and chromosome rearrangement (Tunnacliffe, Liu et al. 1993).         
II.6.3.2.2. Female African Americans 
Seven SNPs (table 28) that are located on the short arm of chromosome 10 were 
associated with eGFR values in female AAs. Six out of these are the same as those 
detected when both sexes were included in analysis (section: II.6.3.2.1.); and the seventh 
one, i.e. rs12266900, is an intergenic variant between MTRNR2L7 gene and RP11-
258F22.1 gene (Ensembl 2016). 
II.6.3.2.3.Male African Americans 
Five intron variants (rs4284824, rs6437089, rs6437092, rs6437097, and rs4973069; see 
table 29) in the INPP5D gene were detected to be associated with eGFR values in male 
AAs; this gene is located on the long arm of chromosome 2 (Ensembl 2016). Four out of 
these five variants have also been reported to be associated with DN in male AAs in this 
study (section: II.6.3.1.3.). 
II.6.3.2.4. European Americans 
76 
 
Association analysis in this group revealed three intergenic variants (rs1373814, 
rs1373813, and rs2120925; see table 30) between EPH receptor B1 (EPHB1) gene and 
RP11-657O9.1 gene, two downstream gene variants (rs10935157 and rs9877871; see 
table 30) of EPHB1 gene, and two intron variants (rs9874828 and rs11715833; see table 
30) on the EPHB1 gene; these SNPs are located on the long arm of chromosome 3 
(Ensembl 2016). 
It has been stated that EPHB1 expression is associated with schizophrenia in Japanese 
population (Kushima, Nakamura et al. 2012). It was detected that its expression enhanced 
in diabetic patients ( Broquères-You, Leré-Déan et al. 2012); however, loss of its 
expression was strongly correlated with colorectal cancer progression (Batlle, Bacani et 
al. 2005).   
II.6.3.2.5.Male European Americans 
rs2118063, rs2704255, rs750343, rs750342, and rs2018041 (table 32) are intergenic 
variants located on the long arm of chromosome 8, between SDC2 gene and CPQ gene; 
rs10086882 (table 32) is an upstream gene variant to CPQ gene (Ensembl 2016). Four out 
of the five intergenic variants have also been described to be associated with DN in male 
EAs in this study (section: II.6.3.1.5.). 
II.6.3.2.6. Mexican Americans 
rs6806039 and rs4680068 (table 33) are intron variants in the CLRN1 gene, rs2222630 
(table 33) is an intron variant in the CD80 gene; rs4407429, rs10511393, rs16830002a, 
rs16830002b and rs16830004 (table 33) are intergenic variants between CD80 gene and 
ADPRH gene. These SNPs are located on the long arm of chromosome 3. rs16830002a 
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and rs16830002b are not listed in any databases; however, rs16830002 is stated to be a 
regulatory region variant (Ensembl 2016). These SNPs have also been found to be 
associated with DN in MAs in this study (section: II.6.3.1.6.). 
rs9313277 and rs12233967 (table 33) are intergenic variants located on the short arm of 
chromosome 5, between small nucleolar RNA host gene 18 (SNHG18) gene and taste 2 
receptor member 1 (TAS2R1) gene (Ensembl 2016). It was shown that there was 
association between TAS2R1 gene expression and type 2 diabetes in Amish families 
(Dotson, Zhang et al. 2008).    
rs2235406 and rs2235412 (table 33) are intron variants in the androgen-dependent TFPI-
regulating protein (ADTRP) gene located on the short arm of chromosome 6 (Ensembl 
2016). The association between ADTRP expression and coronary artery disease has been 
investigated in several studies (Wang, Xu et al. 2011, Guo, Gu et al. 2012, Huang, Peng 
et al. 2015); it might be engaged in metabolic disorders and insulin-dependent 
metabolism control (English, Mandour et al. 2000, Muller, van den Beld et al. 2004).            
II.6.3.2.7.Female Mexican Americans 
rs10272697 and rs41434053 (table 34) are intron variants located on the long arm of 
chromosome 7, in the reelin (RELN) gene (Ensembl 2016). 
It was identified that RELN gene was associated with Crohn disease (He, Fuller et al. 
2013), the age of onset of multiple sclerosis (Baranzini, Wang et al. 2009), subtype of T 
cell leukemia (Zhang, Ding et al. 2012); and sex-dependently was involved in 
schizophrenia (Shifman, Johannesson et al. 2008). It was shown that promoter 
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hypermethylation and decreased expression of this gene was occurred at puberty (Lintas, 
Persico 2010). 
II.6.3.2.8.Male Mexican Americans 
rs13433683, rs1872239 and rs13314357 (table 35) are intergenic variants located on the 
long arm of chromosome 3, between stromal antigen 1 (STAG1) gene and solute carrier 
family 35 member G2 (SLC35G2) gene (Ensembl 2016). 
It was reported that one of the SNPs, significantly associated with three correlated 
inflammatory biomarker traits, was located in STAG1 gene (Benjamin, Dupuis et al. 
2007); it was indicated as one of the candidate genes associated with high density 
lipoprotein (HDL) concentration (Chasman, Paré et al. 2009).     
Although none of the SNPs found in this study has been reported previously to be 
associated with DN or eGFR values, considering the genes functions and SNPs variants, 
the regions and the genes that might be more likely to be associated with DN or changes 
in eGFR values in this study are summarized in table 37 and table 38. These genes could 
be potential candidate genes for DN or variation in eGFR value, and further investigation, 
e.g. linkage analysis, is required to assess their association. 
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Table 37: Genes That Might Be Associated With DN  
Region Associated with Diabetic Nephropathy  
Ethnicity  Start  (BP)  End (BP)  Length (Kb) CHR Gene(s) 
AAs 
173,064,267 173,064,907 1  3q  TMEM212  
106,195,072 106,253,758 59   Xq  RMB41,  NUP62CL 
118,772,536 118,773,182 0.65   Xq  SOWAHD  
Female AAs 
40,078,519 40,079,478 1  2q  SLC8A1-AS1  
18,641,297 38,073,521 19,432  21q  TMPRSS15, KCNJ6 
Male AAs 
25,885,839 25,886,611 1  1p  MAN1C1  
233,667,683 233,671,494 4  2q  INPP5D  
Female EAs 
162,799,773 162,824,472 25  5q  CCNG1, HMMR 
132,279,108 132,299,463 20  8q  RP11-381I15.1, CTD-2501M5.1 
Male EAs 
68,727,655 68,729,751 2  12q  LINC01481  
5,322,063 5,326,099 4  8p  RPL23AP54  
97,712,467 97,716,597 4  8q  SDC2, CPQ 
MAs 
120,759,999 120,773,513 14  3q  CD80, ADPRH 
152,140,530 152,146,140 6  3q  CLRN1  
165,887,308 165,950,952 64  5q  CTB-7E3.1, CTB-63M22.1 
Table 38: Genes That Might Be Associated With GFR Value 
Region Associated with eGFR values 
Ethnicity Start (BP) End (BP) Length (Kb) CHR Gene(s) 
AAs 
96,297,850 106,253,758 9,956 Xq NUP62CL, RMB41, DIAPH2 
37,974,972 38,392,858 418 10p RP11-393J16.4, ZNF33A, ZNF25, ZNF33CP, MTRNR2L7 
Female AAs 37,974,972 38,392,858 418 10p RP11-393J16.4, ZNF33A, ZNF25, ZNF33CP, MTRNR2L7 
Male AAs 233,667,683 233,671,494 4 2q INPP5D 
EAs 136,443,519 136,503,814 60 3q EPHB1, RP11-657O9.1 
Male EAs 97,712,467 97,725,056 13 8q SDC2, CPQ 
Mas 
120,759,999 120,773,513 14 3q CD80, ADPRH 
152,140,530 152,146,140 6 3q CLRN1 
9,658,710 9,659,880 1 5p SNHG18, TAS2R1 
11,851,961 11,862,674 11 6p ADTRP 
Female MAs 103,337,002 103,345,054 8 7q RELN 
Male MAs 137,970,249 138,001,360 31 3q STAG1, SLC35G2 
 
  
80 
 
Chapter 3 
Discussion  
In this study, the results of a genome-wide association scan in the FIND collection that 
have been identified to be associated with the risk of DN and changes in GFR values in 
type 2 diabetes are reported. Since the condition of interest was DN, statistical analyses 
first were conducted for categorical outcome variable; in addition, to detect a genetic 
influence, association with a quantitative outcome variable i.e. GFR value was also 
performed.  
Previous studies revealed that regions on chromosome 7q, 3q, 9q and 20p have been 
linked with DN in Pima Indians (Imperatore, Hanson et al. 1998). Region on 
chromosome 18q has also been found to be associated with DN in Turkish families 
(Vardarli, Baier et al. 2002). In African Americans, regions on chromosomes 3q, 7p and 
18q have been reported to be linked with DN (Bowden, Colicigno et al. 2004). In 
Mexican Americans, a region on chromosome 20q and in European Americans a region 
on chromosome 15q showed evidence of linkage to eGFR in a genome-wide linkage 
study (Thameem, Igo et al. 2013).  
To my knowledge, potential sex dependency with DN or eGFR variation was not 
investigated in these studies. In this study the strongest association with DN have been 
detected on the regions located on the 2p, 4q, 5q, 9q, 12q, 15q and Xq (Table 26), and 
regions located on the 2q, 3q, 7q, 8q, 14q, 15q and Xq are more probably associated with 
eGFR values (Table 36). 
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Since case-control designs are mostly used in the GWA studies, correct selection of cases 
and controls is a crucial issue for the participant ascertainment. Different ascertainment 
models include population-based case-control, case-parent trios and affected sib-pairs 
(ASPs). More significant results and greater odds ratio could be found in unrelated cases 
and controls and case-parent trios compared to ASP designs; however ASPs could show 
more power for detecting an effect in most models except for additive and some epistatic 
models (Howson, Barratt et al. 2005). More association could be achieved in familial 
cases if multiple genes are involved in the development of the disease while genes with 
small effect could be identified in case-control studies (Li, Boehnke et al. 2006). Familial 
cases and/or extreme phenotypes (e.g. selecting cases with early age of onset) can 
increase phenotypic homogeneity. 
In the FIND study, diabetes and nephropathy phenotypes were defined for recruitment of 
participants and the study is based on a case-control design. Both strict and loose criteria 
have been used for inclusion of the cases which were selected from FIND probands or 
siblings (Knowler, Coresh et al. 2005). However, since type 1 diabetes has not been 
differentiated from type 2 diabetes, I excluded those who received insulin as medication 
and had the age of onset of diabetes less than 20 years from the original participants 
before performing statistical analyses; therefore it is quite likely that due to 
misclassification the results have been biased.      
A quantitative biological trait, which is heritable and associated with the disease of 
interest in the population, is defined as an intermediate phenotype or endophenotype. It 
should be associated with causes of disease and co-segregated within families 
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(Gottesman, Gould 2003, Preston, Weinberger 2005, Cannon, Keller 2006). For example, 
plasma levels of adiponectin have been reported as an endophenotype of obesity and 
metabolic syndrome. Then, a variance components linkage analysis, by reporting LOD 
scores, can be used to identify linkage of phenotype to the disease of interest. This 
method also includes a quantitative trait locus (QTL) component (Comuzzie, Funahashi 
et al. 2001). If the trait of interest is common, e.g. obesity, misclassification bias and 
inclusion of the controls which may develop the phenotype of interest later could 
decrease study power; the more stringent case definition is recommended to control this 
type of misclassification. Since both diabetes and diabetic nephropathy are long lasting 
conditions, although controls were selected among members who were long term 
diabetics (≥10 years) with normal renal function, this kind of misclassification bias still 
could happen.   
Other issues in case-control studies include sufficient sample size, cryptic relatedness and 
population stratification; statistical methods such as Principal Component Analysis 
(PCA) are used to detect and control potential population stratification (McCarthy, 
Abecasis et al. 2008). When mating happens between individuals originated from isolated 
ancestral populations, admixture occurs. If exogenous risk factors have to be adjusted in 
association studies, control of admixture fracture at individual level may lead to better 
results than at group level. Unlinked genotypes have been used to detect population 
substructure based on a Bayesian approach with Markov Chain Monte Carlo (MCMC) 
method. Because the convergence findings by these methods might not be reliable, the 
estimated parameters used in these models may not be sensitive, and the computation is 
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very intensive, Tang et al developed a maximum likelihood estimate (MLE) of individual 
admixture (IA) by considering IA and ancestral allele frequency as unknown parameters 
(Tang, Peng et al. 2005).  
Common disease common variant (CD/CV) hypothesis is based on the concept that 
common genetic variations are responsible for the development of common diseases. 
Small effect size (low penetrance) of such variants and involvement of multiple such 
common variants in the inheritance of correlated disorder are consequences of CD/CV 
hypothesis; therefore, the allele frequency in the population and the risk attributed to such 
allele are important factors which influence the sample size required to detect the effect 
and the technical method to be used in the genetic laboratory (Bush, Moore 2012). Either 
direct or indirect association with a trait can be revealed in genetic association studies by 
using LD. In the direct association, the SNP associated with a phenotype is involved 
biologically in the development of the disease and is genotyped directly; in this case the 
SNP is called the functional SNP. If the disease risk SNP is not directly genotyped, a tag 
SNP in high LD with this SNP could be genotyped and be associated with the trait; in this 
case the association is named an indirect association. Therefore, in GWAS an association 
between a SNP and a phenotype should not be considered as the causal variant. 
Microarray technology is used to assay about one million SNPs for each individual. The 
basic concept that four bases in the DNA structure exclusively bind to each other (i.e. 
adenine with thymine and cytosine with guanine, known as hybridization) is the basic 
principle used in microarrays. Since sequencing of the Human Genome Project 
determined the sequence of each SNP, microarrays use this information to identify each 
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SNP genotype (Affymetrix 2009a, Affymetrix 2009). The two most commonly used 
technology developed by Illumina and Affymetrix; chip-based genotyping platforms are 
used in both methods; ordered array of beads and tagging approach is used in Illumina 
technology, while printed-array format and spacing markers within whole genome is used 
in Affymetrix chips. Illumina uses longer DNA sequences than Affymetrix. Illumina 
technology is more expensive, but more specific than Affymetrix method. Next-
generation sequencing methods, which are less expensive, will be used for sequencing the 
whole genome instead of chip-based genotyping platforms in future (Bush, Moore 2012, 
DiStefano, Taverna 2011). 
Different statistical methods are used to represent the results of a genome-wide 
association study. Quantile-quantile plot (Q-Q plot) is used to compare observed test 
statistics distribution with the expected distribution under the null hypothesis; the results 
might be biased if cryptic relatedness and population stratification exist. Single-point 
analyses, with one degree of freedom, such as the Cochran-Armitage test, are powerful 
methods for the analysis of GWAS data. In these methods genotype frequencies for each 
SNP are compared between cases and controls. Adjustment for covariates e.g. PCA can 
be included in the analyses. However, due to multiple testing which influence type 1 error 
rates, adjustment for more than one million independent tests results in a desirable α 
value to be about 5 × 10−8 for reporting significant results. Haplotype-based methods 
and imputation methods are examples of multi-marker analyses. These methods have 
more power to detect associations of variants that have not been genotyped directly. 
Associations of HapMap SNPs, which are not included in the commercial platforms, can 
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be detected more powerfully by imputation methods (McCarthy, Abecasis et al. 2008). If 
multiple hypotheses are tested in one study, classical threshold α = 0.05 could result in 
many spurious significant results. The effect size of an association between a marker 
allele and the trait of interest could be overestimated in the initial studies compared to the 
further studies which are conducted to replicate the reported results; this phenomenon is 
known as "Winner's curse" (Kraft 2008). The novel loci showed association with DN 
and/or eGFR values in this study could be examples of Winner's curse phenomenon. 
Small sample size  influences the study power, incorrect selection of the significance 
thresholds, analysis methods, selective reporting, conflicts of interest in interpretation, 
and the definition of replication have been reported to be the potential reasons which 
could inflate the association findings and in turn lead to false positive results (Ioannidis 
2008).  
GWAS tries to identify the correlation between allele frequencies and the frequency of a 
phenotype by comparing cases and controls; however, the differences in allele 
frequencies could be related to other factors than only to measured outcome. If the 
population of study includes subgroups with different genetic background, which result in 
variation of allele frequencies in these subgroups, and if the disease risk also differs in 
these subgroups, population stratification must be considered as a confounding factor that 
could increase type 1 error (Cardon, Palmer 2003). Ethnicity matched design, selecting 
controls from family members, Transmission Disequilibrium Test (TDT), ethnicity 
adjustment, structured association method, genomic control and PCA are statistical tools 
which are used to resolve the existence of population stratification (Cardon, Palmer 2003, 
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Ziegler, Konig 2010). Different statistical methods are used to detect population 
stratification. In Pritchard and Rosenberg method a number of null and unlinked markers 
are genotyped in cases and controls, then a 𝜒2 test is used to compare the difference in 
allele frequencies between two groups; the sum of the test statistics from each marker is 
used to test the null hypothesis (i.e. there is no population stratification), if the difference 
is significant, population stratification is present (Pritchard, Rosenberg 1999). Devlin and 
Roeder proposed a Bayesian outlier model to estimate the variance inflation factor λ (i.e. 
?̂?  = [𝑚𝑒𝑑𝑖𝑎𝑛(𝑋1, 𝑋2, … , 𝑋𝑛) 0.675⁄ ]
2 to detect population stratification; ?̂? values more 
than 1 means there is population stratification, cryptic relatedness or genotyping error. 
This method in known as "genomic control" and estimated inflation factor ?̂? is used for 
correction of the value of the observed 𝜒2 test statistic (Devlin, Roeder 1999b). 
Population stratification, cryptic relatedness, and the genetic association with the trait can 
also be assessed by quantile-quantile plot (Q-Q plot), which compares the observed 
values with the expected ones (McKnight 2013). In this study, the genomic inflation 
factor ranges between 1.0013 and 1.0439 in different subgroups; therefore, in the 
subgroups, population stratification is less likely to be happened.  
Small sample size, which influences the study power to detect real effect size, might be 
the main reason for not being successful to replicate the results of previous GWA studies. 
Replication and validation methods are used to identify which of the primary GWAS 
results are true associations; hence potential errors and biases should also be noticed and 
addressed. Technical validation could be assessed by re-analyzing the primary samples 
using a different genotyping technology. Using independent samples is another important 
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issue to test replication. Similar genetic model, same phenotype, and the same 
allele/haplotype that have been used in the original studies should be considered in 
designing replication studies. Successful data combination, which is used in meta-
analysis studies, is a potential method to increase the study power.  
Finally, it should be considered that reintroducing biological pathways involved in the 
pathogenesis and development of the disease of interest might explain finding of 
additional susceptible loci with more modest effect sizes e.g. combination of statistical 
evidence with some evaluation of performing contention (McCarthy, Abecasis et al. 
2008).  
This study has several other limitations. Firstly, data used in this study are limited to what 
is provided by NCBI through authorized access. The data show single time information; 
therefore, the trend or variation over time is not available. Secondly, it was not possible 
to test replication of the results found in the FIND collection in another dataset also 
provided by NCBI, named the chronic renal insufficiency cohort (CRIC) study, because 
all participants in CRIC had nephropathy when entered into the study and just one time-
measured values were available. Therefore, the results of this study are not generalizable. 
Thirdly, sample size may not be large enough to detect actual association; in addition, 
after applying quality metrics control the number of individuals encountered in the 
analyses decreased considerably, specifically in Mexican Americans. Since the condition 
of interest has been categorical (case/control design), misclassification of phenotype is 
also likely to happen. 
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Appendix 2: Study Variables  
Variable accession Variable name Variable description 
phv00161411.v1.p1 SubjectId De-identified subject ID 
phv00161412.v1.p1 Sex Sex 
phv00161413.v1.p1 Race Race 
phv00161414.v1.p1 Age Age at enrollment 
phv00161415.v1.p1 DiabeticNephropathy 
Diagnosed with diabetic 
nephropathy 
phv00161416.v1.p1 Diabetes Diagnosed with diabetes 
phv00161417.v1.p1 Diabetes_Duration Age of diabetes diagnosis 
phv00161418.v1.p1 Diabetes_AgeOnset Duration of diabetes 
phv00161419.v1.p1 Retinopathy Retinopathy in either eye? 
phv00161420.v1.p1 KidneyHistology Histological findings in kidneys 
phv00161421.v1.p1 KidneyFailure 
Kidney failure requiring dialysis or 
transplant? 
phv00161422.v1.p1 KidneyFailure_AgeOnset Age of kidney failure 
phv00161423.v1.p1 KidneyFailure_Duration Duration of kidney failure 
phv00161424.v1.p1 Historic_UrineProteinExcretion Historic protein excretion in urine 
phv00161425.v1.p1 Historic_SerumCreatinine Historic serum creatinine 
phv00161426.v1.p1 Historic_UrineProtein Historic urine protein excretion 
phv00161427.v1.p1 Historic_UrineAlbuminSign For values that fall below the 
124 
 
threshold of detection 
phv00161428.v1.p1 Historic_UrineAlbumin Historic urine albumin excretion 
phv00161429.v1.p1 Historic_UrineCreatinine Historic urine creatinine excretion 
phv00161430.v1.p1 Historic_PCR 
Historic urine protein: creatinine 
ratio 
phv00161431.v1.p1 Historic_ACR 
Historic urine albumin: creatinine 
ratio 
phv00161432.v1.p1 Historic_GFR 
Historic (estimated) glomerular 
filtration rate 
phv00161433.v1.p1 Lab_SerumCreatinine Lab serum creatinine 
phv00161434.v1.p1 Lab_UrineProtein Lab urine protein excretion 
phv00161435.v1.p1 Lab_UrineAlbumin Lab urine albumin excretion 
phv00161436.v1.p1 Lab_UrineCreatinine Lab urine creatinine excretion 
phv00161437.v1.p1 Lab_PCR Lab protein-to-creatinine ratio 
phv00161438.v1.p1 Lab_ACR Lab albumin-to-creatinine ratio 
phv00161439.v1.p1 Lab_GFR 
Lab estimated glomerular 
filtration rate 
phv00161440.v1.p1 Lab_HbA1c 
Lab hemoglobin A1c, measured 
as part of study protocol 
phv00161441.v1.p1 CurrentHeight Height at enrollment 
phv00161442.v1.p1 CurrentWeight Weight at enrollment 
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phv00161443.v1.p1 AgeMaxWeight Age when at maximum weight 
phv00161444.v1.p1 HeightMaxWeight Height when at maximum weight 
phv00161445.v1.p1 MaxWeight Maximum weight 
phv00161446.v1.p1 Amputation Did either leg need amputation? 
phv00161447.v1.p1 LegAmputatedLeft Left leg amputated? 
phv00161448.v1.p1 LegAmputatedRight Right leg amputated? 
phv00161449.v1.p1 HBP High blood pressure 
phv00161450.v1.p1 HBP_Duration Duration of high blood pressure 
phv00161451.v1.p1 ACE_ARBs Taking ACE inhibitors or ARBS? 
phv00161452.v1.p1 Insulin Taking insulin? 
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Appendix 3: African Americans log files 
1) sex_check.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Connecting to web...  OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ sex_check.log ] 
Analysis started: Wed May 20 01:22:58 2015 
 
Options in effect: 
 --bfile FIND_AA_5plus 
 --check-sex 
 --out sex_check 
 
Reading map (extended format) from [ FIND_AA_5plus.bim ]  
932534 markers to be included from [ FIND_AA_5plus.bim ] 
Reading pedigree information from [ FIND_AA_5plus.fam ]  
864 individuals read from [ FIND_AA_5plus.fam ]  
859 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
581 cases, 278 controls and 5 missing 
291 males, 573 females, and 0 of unspecified sex 
Reading genotype bitfile from [ FIND_AA_5plus.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Before frequency and genotyping pruning, there are 932534 SNPs 
864 founders and 0 non-founders found 
36273 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ sex_check.hh ] 
24247 SNPs with no founder genotypes observed 
Warning, MAF set to 0 for these SNPs (see --nonfounders) 
Writing list of these SNPs to [ sex_check.nof ] 
Total genotyping rate in remaining individuals is 0.964565 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 932534 SNPs 
After filtering, 581 cases, 278 controls and 5 missing 
After filtering, 291 males, 573 females, and 0 of unspecified sex 
Converting data to Individual-major format 
Writing X-chromosome sex check results to [ sex_check.sexcheck ]  
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Analysis finished: Wed May 20 01:25:27 2015 
2) genomissing.log  
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found... OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ genomissing.log ] 
Analysis started: Wed May 20 01:29:52 2015 
 
Options in effect: 
 --bfile FIND_AA_5plus 
 --missing 
 --out genomissing 
 
Reading map (extended format) from [ FIND_AA_5plus.bim ]  
932534 markers to be included from [ FIND_AA_5plus.bim ] 
Reading pedigree information from [ FIND_AA_5plus.fam ]  
864 individuals read from [ FIND_AA_5plus.fam ]  
859 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
581 cases, 278 controls and 5 missing 
291 males, 573 females, and 0 of unspecified sex 
Reading genotype bitfile from [ FIND_AA_5plus.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Before frequency and genotyping pruning, there are 932534 SNPs 
864 founders and 0 non-founders found 
36273 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ genomissing.hh ] 
24247 SNPs with no founder genotypes observed 
Warning, MAF set to 0 for these SNPs (see --nonfounders) 
Writing list of these SNPs to [ genomissing.nof ] 
Writing individual missingness information to [ genomissing.imiss ]  
Writing locus missingness information to [ genomissing.lmiss ]  
Total genotyping rate in remaining individuals is 0.96452 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 932534 SNPs 
After filtering, 581 cases, 278 controls and 5 missing 
After filtering, 291 males, 573 females, and 0 of unspecified sex 
 
Analysis finished: Wed May 20 01:32:19 2015 
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3) FIND_AA_5plus_ibd.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found... OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ FIND_AA_5plus_ibd.log ] 
Analysis started: Wed May 20 03:06:21 2015 
 
Options in effect: 
 --bfile FIND_AA_5plus_sex_imputed_independentSNPs 
 --genome 
 --out FIND_AA_5plus_ibd 
 
Reading map (extended format) from [ FIND_AA_5plus_sex_imputed_independentSNPs.bim ]  
312743 markers to be included from [ FIND_AA_5plus_sex_imputed_independentSNPs.bim ] 
Reading pedigree information from [ FIND_AA_5plus_sex_imputed_independentSNPs.fam ]  
853 individuals read from [ FIND_AA_5plus_sex_imputed_independentSNPs.fam ]  
853 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
575 cases, 278 controls and 0 missing 
286 males, 567 females, and 0 of unspecified sex 
Reading genotype bitfile from [ FIND_AA_5plus_sex_imputed_independentSNPs.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Before frequency and genotyping pruning, there are 312743 SNPs 
853 founders and 0 non-founders found 
22335 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ FIND_AA_5plus_ibd.hh ] 
1 SNPs with no founder genotypes observed 
Warning, MAF set to 0 for these SNPs (see --nonfounders) 
Writing list of these SNPs to [ FIND_AA_5plus_ibd.nof ] 
Total genotyping rate in remaining individuals is 0.994493 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 312743 SNPs 
After filtering, 575 cases, 278 controls and 0 missing 
After filtering, 286 males, 567 females, and 0 of unspecified sex 
Converting data to Individual-major format 
Writing whole genome IBS/IBD information to [ FIND_AA_5plus_ibd.genome ]  
Filtering output to include pairs with ( 0 <= PI-HAT <= 1 ) 
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Analysis finished: Wed May 20 05:08:36 2015 
 
4) FIND_AA_5plus_sex_problem_removed.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found... OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ FIND_AA_5plus_sex_problem_removed.log ] 
Analysis started: Sun Jul 19 13:59:00 2015 
 
Options in effect: 
 --bfile FIND_AA_5plus 
 --remove sex_problem.txt 
 --make-bed 
 --out FIND_AA_5plus_sex_problem_removed 
 
Reading map (extended format) from [ FIND_AA_5plus.bim ]  
932534 markers to be included from [ FIND_AA_5plus.bim ] 
Reading pedigree information from [ FIND_AA_5plus.fam ]  
864 individuals read from [ FIND_AA_5plus.fam ]  
859 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
581 cases, 278 controls and 5 missing 
291 males, 573 females, and 0 of unspecified sex 
Reading genotype bitfile from [ FIND_AA_5plus.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Reading individuals to remove [ sex_problem.txt ] ... 11 read 
11 individuals removed with --remove option 
Before frequency and genotyping pruning, there are 932534 SNPs 
853 founders and 0 non-founders found 
36273 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ FIND_AA_5plus_sex_problem_removed.hh ] 
24247 SNPs with no founder genotypes observed 
Warning, MAF set to 0 for these SNPs (see --nonfounders) 
Writing list of these SNPs to [ FIND_AA_5plus_sex_problem_removed.nof ] 
Total genotyping rate in remaining individuals is 0.970195 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 932534 SNPs 
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After filtering, 575 cases, 278 controls and 0 missing 
After filtering, 286 males, 567 females, and 0 of unspecified sex 
Writing pedigree information to [ FIND_AA_5plus_sex_problem_removed.fam ]  
Writing map (extended format) information to [ FIND_AA_5plus_sex_problem_removed.bim ]  
Writing genotype bitfile to [ FIND_AA_5plus_sex_problem_removed.bed ]  
Using (default) SNP-major mode 
 
Analysis finished: Sun Jul 19 14:00:59 2015 
 
5) FIND_AA_5plus_sex_imputed.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found... OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ FIND_AA_5plus_sex_imputed.log ] 
Analysis started: Sun Jul 19 14:11:17 2015 
 
Options in effect: 
 --bfile FIND_AA_5plus_sex_problem_removed 
 --impute-sex 
 --make-bed 
 --out FIND_AA_5plus_sex_imputed 
 
Reading map (extended format) from [ FIND_AA_5plus_sex_problem_removed.bim ]  
932534 markers to be included from [ FIND_AA_5plus_sex_problem_removed.bim ] 
Reading pedigree information from [ FIND_AA_5plus_sex_problem_removed.fam ]  
853 individuals read from [ FIND_AA_5plus_sex_problem_removed.fam ]  
853 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
575 cases, 278 controls and 0 missing 
286 males, 567 females, and 0 of unspecified sex 
Reading genotype bitfile from [ FIND_AA_5plus_sex_problem_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Before frequency and genotyping pruning, there are 932534 SNPs 
853 founders and 0 non-founders found 
36273 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ FIND_AA_5plus_sex_imputed.hh ] 
24247 SNPs with no founder genotypes observed 
Warning, MAF set to 0 for these SNPs (see --nonfounders) 
Writing list of these SNPs to [ FIND_AA_5plus_sex_imputed.nof ] 
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Total genotyping rate in remaining individuals is 0.970195 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 932534 SNPs 
After filtering, 575 cases, 278 controls and 0 missing 
After filtering, 286 males, 567 females, and 0 of unspecified sex 
Converting data to Individual-major format 
Writing X-chromosome sex check results to [ FIND_AA_5plus_sex_imputed.sexcheck ]  
Writing pedigree information to [ FIND_AA_5plus_sex_imputed.fam ]  
Writing map (extended format) information to [ FIND_AA_5plus_sex_imputed.bim ]  
Writing genotype bitfile to [ FIND_AA_5plus_sex_imputed.bed ]  
Using (default) SNP-major mode 
Converting data to SNP-major format 
 
Analysis finished: Sun Jul 19 14:16:40 2015 
 
6) FIND_AA_5plus_pruning.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found... OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ FIND_AA_5plus_pruning.log ] 
Analysis started: Sun Jul 19 14:53:48 2015 
 
Options in effect: 
 --bfile FIND_AA_5plus 
 --indep 50 5 2 
 --out FIND_AA_5plus_pruning 
 
Reading map (extended format) from [ FIND_AA_5plus.bim ]  
932534 markers to be included from [ FIND_AA_5plus.bim ] 
Reading pedigree information from [ FIND_AA_5plus.fam ]  
864 individuals read from [ FIND_AA_5plus.fam ]  
859 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
581 cases, 278 controls and 5 missing 
291 males, 573 females, and 0 of unspecified sex 
Reading genotype bitfile from [ FIND_AA_5plus.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Before frequency and genotyping pruning, there are 932534 SNPs 
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864 founders and 0 non-founders found 
36273 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ FIND_AA_5plus_pruning.hh ] 
24247 SNPs with no founder genotypes observed 
Warning, MAF set to 0 for these SNPs (see --nonfounders) 
Writing list of these SNPs to [ FIND_AA_5plus_pruning.nof ] 
Total genotyping rate in remaining individuals is 0.96452 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 932534 SNPs 
After filtering, 581 cases, 278 controls and 5 missing 
After filtering, 291 males, 573 females, and 0 of unspecified sex 
Performing LD-based pruning... 
Writing pruned-in SNPs to [ FIND_AA_5plus_pruning.prune.in ] 
Writing pruned-out SNPs to [ FIND_AA_5plus_pruning.prune.out ] 
Scanning from chromosome 1 to Y 
 
Scan region on chromosome 1 from [ rs10458597 ] to [ rs7521920 ] 
For chromosome 1, 48947 SNPs pruned out, 24399 remaining 
Scan region on chromosome 2 from [ rs10181821 ] to [ rs12478296 ] 
For chromosome 2, 51460 SNPs pruned out, 24404 remaining 
Scan region on chromosome 3 from [ rs13089679 ] to [ rs2313099 ] 
For chromosome 3, 41972 SNPs pruned out, 20295 remaining 
Scan region on chromosome 4 from [ rs1988520 ] to [ rs1474523 ] 
For chromosome 4, 38716 SNPs pruned out, 18781 remaining 
Scan region on chromosome 5 from [ rs7704488 ] to [ rs6894609 ] 
For chromosome 5, 38816 SNPs pruned out, 19092 remaining 
Scan region on chromosome 6 from [ rs4959515 ] to [ rs6931065 ] 
For chromosome 6, 38946 SNPs pruned out, 18839 remaining 
Scan region on chromosome 7 from [ rs12666071 ] to [ rs1985369 ] 
For chromosome 7, 32157 SNPs pruned out, 16165 remaining 
Scan region on chromosome 8 from [ rs7462951 ] to [ rs6599566 ] 
For chromosome 8, 34013 SNPs pruned out, 15977 remaining 
Scan region on chromosome 9 from [ rs2811026 ] to [ rs7863719 ] 
For chromosome 9, 28576 SNPs pruned out, 14077 remaining 
Scan region on chromosome 10 from [ rs11252546 ] to [ rs12218790 ] 
For chromosome 10, 33222 SNPs pruned out, 16323 remaining 
Scan region on chromosome 11 from [ rs3802985 ] to [ rs11224232 ] 
For chromosome 11, 30980 SNPs pruned out, 14874 remaining 
Scan region on chromosome 12 from [ rs1500095 ] to [ rs11147298 ] 
For chromosome 12, 28732 SNPs pruned out, 15050 remaining 
Scan region on chromosome 13 from [ rs1747380 ] to [ rs9525207 ] 
For chromosome 13, 23412 SNPs pruned out, 11707 remaining 
Scan region on chromosome 14 from [ rs4983173 ] to [ rs7144412 ] 
For chromosome 14, 18955 SNPs pruned out, 9969 remaining 
Scan region on chromosome 15 from [ rs12905389 ] to [ rs1533309 ] 
For chromosome 15, 17124 SNPs pruned out, 9742 remaining 
Scan region on chromosome 16 from [ rs41340949 ] to [ rs4785775 ] 
For chromosome 16, 18387 SNPs pruned out, 10238 remaining 
Scan region on chromosome 17 from [ rs6565733 ] to [ rs4986109 ] 
For chromosome 17, 12761 SNPs pruned out, 8540 remaining 
Scan region on chromosome 18 from [ rs7235612 ] to [ rs7236400 ] 
For chromosome 18, 17591 SNPs pruned out, 9612 remaining 
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Scan region on chromosome 19 from [ rs8100066 ] to [ rs8110595 ] 
For chromosome 19, 6998 SNPs pruned out, 5358 remaining 
Scan region on chromosome 20 from [ rs4814683 ] to [ rs6062363 ] 
For chromosome 20, 15037 SNPs pruned out, 8430 remaining 
Scan region on chromosome 21 from [ rs169757 ] to [ rs7116 ] 
For chromosome 21, 8182 SNPs pruned out, 4748 remaining 
Scan region on chromosome 22 from [ rs4389403 ] to [ rs28729663 ] 
For chromosome 22, 7129 SNPs pruned out, 4901 remaining 
Scan region on chromosome 23 from [ rs6423165 ] to [ rs2981835 ] 
For chromosome 23, 26820 SNPs pruned out, 11179 remaining 
Scan region on chromosome 24 from [ rs2075640 ] to [ rs9724556 ] 
For chromosome 24, 858 SNPs pruned out, 43 remaining 
 
Analysis finished: Sun Jul 19 16:04:18 2015 
 
7) FIND_AA_5plus_sex_imputed_independentSNPs 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found... OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ FIND_AA_5plus_sex_imputed_independentSNPs.log ] 
Analysis started: Sun Jul 19 16:09:25 2015 
 
Options in effect: 
 --bfile FIND_AA_5plus_sex_imputed 
 --extract FIND_AA_5plus_pruning.prune.in 
 --make-bed 
 --out FIND_AA_5plus_sex_imputed_independentSNPs 
 
Reading map (extended format) from [ FIND_AA_5plus_sex_imputed.bim ]  
932534 markers to be included from [ FIND_AA_5plus_sex_imputed.bim ] 
Reading pedigree information from [ FIND_AA_5plus_sex_imputed.fam ]  
853 individuals read from [ FIND_AA_5plus_sex_imputed.fam ]  
853 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
575 cases, 278 controls and 0 missing 
286 males, 567 females, and 0 of unspecified sex 
Reading genotype bitfile from [ FIND_AA_5plus_sex_imputed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Reading list of SNPs to extract [ FIND_AA_5plus_pruning.prune.in ] ... 312743 read 
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Before frequency and genotyping pruning, there are 312743 SNPs 
853 founders and 0 non-founders found 
22335 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ FIND_AA_5plus_sex_imputed_independentSNPs.hh ] 
1 SNPs with no founder genotypes observed 
Warning, MAF set to 0 for these SNPs (see --nonfounders) 
Writing list of these SNPs to [ FIND_AA_5plus_sex_imputed_independentSNPs.nof ] 
Total genotyping rate in remaining individuals is 0.994577 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 312743 SNPs 
After filtering, 575 cases, 278 controls and 0 missing 
After filtering, 286 males, 567 females, and 0 of unspecified sex 
Writing pedigree information to [ FIND_AA_5plus_sex_imputed_independentSNPs.fam ]  
Writing map (extended format) information to [ FIND_AA_5plus_sex_imputed_independentSNPs.bim ]  
Writing genotype bitfile to [ FIND_AA_5plus_sex_imputed_independentSNPs.bed ]  
Using (default) SNP-major mode 
 
Analysis finished: Sun Jul 19 16:10:35 2015 
 
8) FIND_AA_5plus_sex_imputed_people_snp_removed 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found... OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ FIND_AA_5plus_sex_imputed_people_snp_removed.log ] 
Analysis started: Sun Jul 19 16:18:55 2015 
 
Options in effect: 
 --bfile FIND_AA_5plus_sex_imputed 
 --remove people_missing0.03.txt 
 --exclude snplist_missing0.05.txt 
 --make-bed 
 --out FIND_AA_5plus_sex_imputed_people_snp_removed 
 
Reading map (extended format) from [ FIND_AA_5plus_sex_imputed.bim ]  
932534 markers to be included from [ FIND_AA_5plus_sex_imputed.bim ] 
Reading pedigree information from [ FIND_AA_5plus_sex_imputed.fam ]  
853 individuals read from [ FIND_AA_5plus_sex_imputed.fam ]  
853 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
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Missing phenotype value is also -9 
575 cases, 278 controls and 0 missing 
286 males, 567 females, and 0 of unspecified sex 
Reading genotype bitfile from [ FIND_AA_5plus_sex_imputed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Reading list of SNPs to exclude [ snplist_missing0.05.txt ] ... 35692 read 
Reading individuals to remove [ people_missing0.03.txt ] ... 177 read 
177 individuals removed with --remove option 
Before frequency and genotyping pruning, there are 896842 SNPs 
676 founders and 0 non-founders found 
224 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ 
FIND_AA_5plus_sex_imputed_people_snp_removed.hh ] 
Total genotyping rate in remaining individuals is 0.998683 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 896842 SNPs 
After filtering, 451 cases, 225 controls and 0 missing 
After filtering, 218 males, 458 females, and 0 of unspecified sex 
Writing pedigree information to [ FIND_AA_5plus_sex_imputed_people_snp_removed.fam ]  
Writing map (extended format) information to [ FIND_AA_5plus_sex_imputed_people_snp_removed.bim 
]  
Writing genotype bitfile to [ FIND_AA_5plus_sex_imputed_people_snp_removed.bed ]  
Using (default) SNP-major mode 
 
Analysis finished: Sun Jul 19 16:20:39 2015 
 
9) FIND_AA_5plus_sex_imputed_people_snp_t1d_removed 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found... OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ FIND_AA_5plus_sex_imputed_people_snp_t1d_removed.log ] 
Analysis started: Sun Jul 19 16:57:50 2015 
 
Options in effect: 
 --bfile FIND_AA_5plus_sex_imputed_people_snp_removed 
 --remove AA_Age19andless_insulin.txt 
 --make-bed 
 --out FIND_AA_5plus_sex_imputed_people_snp_t1d_removed 
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Reading map (extended format) from [ FIND_AA_5plus_sex_imputed_people_snp_removed.bim ]  
896842 markers to be included from [ FIND_AA_5plus_sex_imputed_people_snp_removed.bim ] 
Reading pedigree information from [ FIND_AA_5plus_sex_imputed_people_snp_removed.fam ]  
676 individuals read from [ FIND_AA_5plus_sex_imputed_people_snp_removed.fam ]  
676 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
451 cases, 225 controls and 0 missing 
218 males, 458 females, and 0 of unspecified sex 
Reading genotype bitfile from [ FIND_AA_5plus_sex_imputed_people_snp_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Reading individuals to remove [ AA_Age19andless_insulin.txt ] ... 14 read 
14 individuals removed with --remove option 
Before frequency and genotyping pruning, there are 896842 SNPs 
662 founders and 0 non-founders found 
214 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_removed.hh ] 
Total genotyping rate in remaining individuals is 0.998681 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 896842 SNPs 
After filtering, 441 cases, 221 controls and 0 missing 
After filtering, 212 males, 450 females, and 0 of unspecified sex 
Writing pedigree information to [ FIND_AA_5plus_sex_imputed_people_snp_t1d_removed.fam ]  
Writing map (extended format) information to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_removed.bim ]  
Writing genotype bitfile to [ FIND_AA_5plus_sex_imputed_people_snp_t1d_removed.bed ]  
Using (default) SNP-major mode 
 
Analysis finished: Sun Jul 19 16:59:22 2015 
 
10) FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found...Problem connecting to web 
 
Writing this text to log file [ FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.log ] 
Analysis started: Sat Jul 25 14:00:37 2015 
 
Options in effect: 
 --bfile FIND_AA_5plus_sex_imputed_people_snp_t1d_removed 
 --remove PI_HAT0.1875.txt 
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 --make-bed 
 --out FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed 
 
Reading map (extended format) from [ FIND_AA_5plus_sex_imputed_people_snp_t1d_removed.bim ]  
896842 markers to be included from [ FIND_AA_5plus_sex_imputed_people_snp_t1d_removed.bim ] 
Reading pedigree information from [ FIND_AA_5plus_sex_imputed_people_snp_t1d_removed.fam ]  
662 individuals read from [ FIND_AA_5plus_sex_imputed_people_snp_t1d_removed.fam ]  
662 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
441 cases, 221 controls and 0 missing 
212 males, 450 females, and 0 of unspecified sex 
Reading genotype bitfile from [ FIND_AA_5plus_sex_imputed_people_snp_t1d_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Reading individuals to remove [ PI_HAT0.1875.txt ] ... 29 read 
26 individuals removed with --remove option 
Before frequency and genotyping pruning, there are 896842 SNPs 
636 founders and 0 non-founders found 
203 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.hh ] 
Total genotyping rate in remaining individuals is 0.998677 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 896842 SNPs 
After filtering, 426 cases, 210 controls and 0 missing 
After filtering, 199 males, 437 females, and 0 of unspecified sex 
Writing pedigree information to [ FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.fam 
]  
Writing map (extended format) information to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.bim ]  
Writing genotype bitfile to [ FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.bed ]  
Using (default) SNP-major mode 
 
Analysis finished: Sat Jul 25 14:02:07 2015 
 
11) hwe.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found...Problem connecting to web 
 
Writing this text to log file [ hwe.log ] 
Analysis started: Sat Jul 25 14:27:05 2015 
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Options in effect: 
 --bfile FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed 
 --hardy 
 --nonfounders 
 --out hwe 
 
Reading map (extended format) from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.bim ]  
896842 markers to be included from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.bim ] 
Reading pedigree information from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.fam ]  
636 individuals read from [ FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.fam ]  
636 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
426 cases, 210 controls and 0 missing 
199 males, 437 females, and 0 of unspecified sex 
Reading genotype bitfile from [ FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Before frequency and genotyping pruning, there are 896842 SNPs 
636 founders and 0 non-founders found 
203 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ hwe.hh ] 
Writing Hardy-Weinberg tests (all individuals) to [ hwe.hwe ]  
1690 markers to be excluded based on HWE test ( p <= 0.001 ) 
 3152 markers failed HWE test in cases 
 1690 markers failed HWE test in controls 
Total genotyping rate in remaining individuals is 0.998677 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 895152 SNPs 
After filtering, 426 cases, 210 controls and 0 missing 
After filtering, 199 males, 437 females, and 0 of unspecified sex 
 
Analysis finished: Sat Jul 25 14:30:02 2015 
 
12) freq.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found...Problem connecting to web 
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Writing this text to log file [ freq.log ] 
Analysis started: Sat Jul 25 14:36:11 2015 
 
Options in effect: 
 --bfile FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed 
 --freq 
 --out freq 
 
Reading map (extended format) from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.bim ]  
896842 markers to be included from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.bim ] 
Reading pedigree information from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.fam ]  
636 individuals read from [ FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.fam ]  
636 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
426 cases, 210 controls and 0 missing 
199 males, 437 females, and 0 of unspecified sex 
Reading genotype bitfile from [ FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Before frequency and genotyping pruning, there are 896842 SNPs 
636 founders and 0 non-founders found 
203 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ freq.hh ] 
Writing allele frequencies (founders-only) to [ freq.frq ]  
 
Analysis finished: Sat Jul 25 14:37:20 2015 
 
13) FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_removed.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found...Problem connecting to web 
 
Writing this text to log file [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_removed.log ] 
Analysis started: Sat Jul 25 15:31:51 2015 
 
Options in effect: 
 --bfile FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed 
 --exclude freq0.05.txt 
 --make-bed 
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 --out FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_removed 
 
** For gPLINK compatibility, do not use '.' in --out ** 
Reading map (extended format) from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.bim ]  
896842 markers to be included from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.bim ] 
Reading pedigree information from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.fam ]  
636 individuals read from [ FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.fam ]  
636 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
426 cases, 210 controls and 0 missing 
199 males, 437 females, and 0 of unspecified sex 
Reading genotype bitfile from [ FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Reading list of SNPs to exclude [ freq0.05.txt ] ... 111642 read 
Before frequency and genotyping pruning, there are 785200 SNPs 
636 founders and 0 non-founders found 
54 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_removed.hh ] 
Total genotyping rate in remaining individuals is 0.998696 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 785200 SNPs 
After filtering, 426 cases, 210 controls and 0 missing 
After filtering, 199 males, 437 females, and 0 of unspecified sex 
Writing pedigree information to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_removed.fam ]  
Writing map (extended format) information to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_removed.bim ]  
Writing genotype bitfile to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_removed.bed ]  
Using (default) SNP-major mode 
 
Analysis finished: Sat Jul 25 15:33:13 2015 
 
14) FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found...Problem connecting to web 
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Writing this text to log file [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.log ] 
Analysis started: Sat Jul 25 15:36:33 2015 
 
Options in effect: 
 --bfile FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_removed 
 --exclude hwe0.0001.txt 
 --make-bed 
 --out FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed 
 
** For gPLINK compatibility, do not use '.' in --out ** 
Reading map (extended format) from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_removed.bim ]  
785200 markers to be included from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_removed.bim ] 
Reading pedigree information from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_removed.fam ]  
636 individuals read from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_removed.fam ]  
636 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
426 cases, 210 controls and 0 missing 
199 males, 437 females, and 0 of unspecified sex 
Reading genotype bitfile from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Reading list of SNPs to exclude [ hwe0.0001.txt ] ... 3988 read 
Before frequency and genotyping pruning, there are 782810 SNPs 
636 founders and 0 non-founders found 
54 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.hh ] 
Total genotyping rate in remaining individuals is 0.998719 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 782810 SNPs 
After filtering, 426 cases, 210 controls and 0 missing 
After filtering, 199 males, 437 females, and 0 of unspecified sex 
Writing pedigree information to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.fam ]  
Writing map (extended format) information to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bim ]  
Writing genotype bitfile to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bed ]  
Using (default) SNP-major mode 
 
Analysis finished: Sat Jul 25 15:37:52 2015 
 
15) FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed_male.log 
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@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found...Problem connecting to web 
 
Writing this text to log file [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed_male.log ] 
Analysis started: Sat Jul 25 15:47:43 2015 
 
Options in effect: 
 --bfile FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_hwe0.0001_removed 
 --remove FemaleAA.txt 
 --make-bed 
 --out 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed_male 
 
** For gPLINK compatibility, do not use '.' in --out ** 
Reading map (extended format) from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_hwe0.0001_removed.bim ]  
782810 markers to be included from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_hwe0.0001_removed.bim ] 
Reading pedigree information from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_hwe0.0001_removed.fam ]  
636 individuals read from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_hwe0.0001_removed.fam ]  
636 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
426 cases, 210 controls and 0 missing 
199 males, 437 females, and 0 of unspecified sex 
Reading genotype bitfile from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_hwe0.0001_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Reading individuals to remove [ FemaleAA.txt ] ... 437 read 
437 individuals removed with --remove option 
Before frequency and genotyping pruning, there are 782810 SNPs 
199 founders and 0 non-founders found 
54 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed_male.hh ] 
Total genotyping rate in remaining individuals is 0.99889 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 782810 SNPs 
After filtering, 155 cases, 44 controls and 0 missing 
After filtering, 199 males, 0 females, and 0 of unspecified sex 
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Writing pedigree information to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed_male.fam ]  
Writing map (extended format) information to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed_male.bim ]  
Writing genotype bitfile to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed_male.bed ]  
Using (default) SNP-major mode 
 
Analysis finished: Sat Jul 25 15:48:41 2015 
 
16) 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed_female.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found...Problem connecting to web 
 
Writing this text to log file [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed_female.log ] 
Analysis started: Sat Jul 25 15:49:13 2015 
 
Options in effect: 
 --bfile FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_hwe0.0001_removed 
 --remove maleAA.txt 
 --make-bed 
 --out 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed_female 
 
** For gPLINK compatibility, do not use '.' in --out ** 
Reading map (extended format) from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_hwe0.0001_removed.bim ]  
782810 markers to be included from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_hwe0.0001_removed.bim ] 
Reading pedigree information from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_hwe0.0001_removed.fam ]  
636 individuals read from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_hwe0.0001_removed.fam ]  
636 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
426 cases, 210 controls and 0 missing 
199 males, 437 females, and 0 of unspecified sex 
Reading genotype bitfile from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_hwe0.0001_removed.bed ]  
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Detected that binary PED file is v1.00 SNP-major mode 
Reading individuals to remove [ maleAA.txt ] ... 199 read 
199 individuals removed with --remove option 
Before frequency and genotyping pruning, there are 782810 SNPs 
437 founders and 0 non-founders found 
Total genotyping rate in remaining individuals is nan 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 782810 SNPs 
After filtering, 271 cases, 166 controls and 0 missing 
After filtering, 0 males, 437 females, and 0 of unspecified sex 
Writing pedigree information to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed_female.fam ]  
Writing map (extended format) information to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed_female.bim ]  
Writing genotype bitfile to [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed_female.bed ]  
Using (default) SNP-major mode 
 
Analysis finished: Sat Jul 25 15:50:27 2015 
 
17) AA_quantitative_all.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Connecting to web...  OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ AA_q_all.log ] 
Analysis started: Sat Aug 08 15:01:49 2015 
 
Options in effect: 
 --bfile 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed 
 --pheno GFR_Phen.txt 
 --make-bed 
 --out AA_q_all 
 
Reading map (extended format) from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bim ]  
782810 markers to be included from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bim ] 
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Reading pedigree information from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.fam ]  
636 individuals read from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.fam ]  
636 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
426 cases, 210 controls and 0 missing 
199 males, 437 females, and 0 of unspecified sex 
Reading genotype bitfile from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Reading alternate phenotype from [ GFR_Phen.txt ]  
633 individuals with non-missing alternate phenotype 
Assuming a quantitative trait 
Missing phenotype value is -9 
Before frequency and genotyping pruning, there are 782810 SNPs 
636 founders and 0 non-founders found 
54 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ AA_q_all.hh ] 
Total genotyping rate in remaining individuals is 0.998719 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 782810 SNPs 
After filtering, 633 individuals with non-missing status 
After filtering, 199 males, 437 females, and 0 of unspecified sex 
Writing pedigree information to [ AA_q_all.fam ]  
Writing map (extended format) information to [ AA_q_all.bim ]  
Writing genotype bitfile to [ AA_q_all.bed ]  
Using (default) SNP-major mode 
 
Analysis finished: Sat Aug 08 15:03:03 2015 
 
18) AA_ibs_all.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found... OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ plink.log ] 
Analysis started: Sat Aug 08 16:11:51 2015 
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Options in effect: 
 --bfile 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed 
 --read-genome FIND_AA_5plus_ibd.genome 
 --ibs-test 
 
Reading map (extended format) from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bim ]  
782810 markers to be included from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bim ] 
Reading pedigree information from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.fam ]  
636 individuals read from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.fam ]  
636 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
426 cases, 210 controls and 0 missing 
199 males, 437 females, and 0 of unspecified sex 
Reading genotype bitfile from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Before frequency and genotyping pruning, there are 782810 SNPs 
636 founders and 0 non-founders found 
54 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ plink.hh ] 
Total genotyping rate in remaining individuals is 0.998719 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 782810 SNPs 
After filtering, 426 cases, 210 controls and 0 missing 
After filtering, 199 males, 437 females, and 0 of unspecified sex 
Converting data to Individual-major format 
Clustering individuals based on genome-wide IBS 
Merge distance p-value constraint = 0 
Reading genome-wide IBS estimates from [ FIND_AA_5plus_ibd.genome ]  
Set to permute within 1 cluster(s) 
 
Between-group IBS (mean, SD) = 0.817981, 0.00336465 
In-group (2) IBS (mean, SD) = 0.81839, 0.00293358 
In-group (1) IBS (mean, SD) = 0.817598, 0.00367504 
Approximate proportion of variance between group = 0.00155461 
IBS group-difference empirical p-values: 
 
 T1: Case/control less similar                     p = 0.0137299 
 T2: Case/control more similar                     p = 0.98628 
 
 T3: Case/case less similar than control/control   p = 0.98632 
 T4: Case/case more similar than control/control   p = 0.0136899 
 
 T5: Case/case less similar                        p = 0.98635 
 T6: Case/case more similar                        p = 0.0136599 
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 T7: Control/control less similar                  p = 0.0136299 
 T8: Control/control more similar                  p = 0.98638 
 
 T9: Case/case less similar than case/control      p = 0.9863 
T10: Case/case more similar than case/control      p = 0.0137099 
 
T11: Control/control less similar than case/control p = 0.9816 
T12: Control/control more similar than case/control p = 0.0184098 
 
Analysis finished: Sat Aug 08 16:23:29 2015 
19) AA_ibd_all.log  
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found... OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ plink.log ] 
Analysis started: Sat Aug 08 22:52:34 2015 
 
Options in effect: 
 --bfile 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed 
 --read-genome FIND_AA_5plus_ibd.genome 
 --cluster 
 --neighbour 1 5 
 
Reading map (extended format) from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bim ]  
782810 markers to be included from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bim ] 
Reading pedigree information from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.fam ]  
636 individuals read from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.fam ]  
636 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
426 cases, 210 controls and 0 missing 
199 males, 437 females, and 0 of unspecified sex 
Reading genotype bitfile from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bed ]  
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Detected that binary PED file is v1.00 SNP-major mode 
Before frequency and genotyping pruning, there are 782810 SNPs 
636 founders and 0 non-founders found 
54 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ plink.hh ] 
Total genotyping rate in remaining individuals is 0.998719 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 782810 SNPs 
After filtering, 426 cases, 210 controls and 0 missing 
After filtering, 199 males, 437 females, and 0 of unspecified sex 
Converting data to Individual-major format 
Clustering individuals based on genome-wide IBS 
Merge distance p-value constraint = 0 
Outlier detection based on neighbours 1 to 5 
Reading genome-wide IBS estimates from [ FIND_AA_5plus_ibd.genome ]  
Of these, 201930 are pairable based on constraints 
Writing individual neighbour/outlier statatistics to [ plink.nearest ] 
Writing cluster progress to [ plink.cluster0 ] 
Writing cluster solution (1) [ plink.cluster1 ] 
Writing cluster solution (2) [ plink.cluster2 ] 
Writing cluster solution (3) [ plink.cluster3 ] 
 
Analysis finished: Sat Aug 08 22:54:16 2015 
 
20) AA_mds_plot_all.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found... OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ plink.log ] 
Analysis started: Sun Aug 09 21:37:32 2015 
 
Options in effect: 
 --bfile 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed 
 --read-genome FIND_AA_5plus_ibd.genome 
 --cluster 
 --mds-plot 4 
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Reading map (extended format) from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bim ]  
782810 markers to be included from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bim ] 
Reading pedigree information from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.fam ]  
636 individuals read from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.fam ]  
636 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
426 cases, 210 controls and 0 missing 
199 males, 437 females, and 0 of unspecified sex 
Reading genotype bitfile from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Before frequency and genotyping pruning, there are 782810 SNPs 
636 founders and 0 non-founders found 
54 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ plink.hh ] 
Total genotyping rate in remaining individuals is 0.998719 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 782810 SNPs 
After filtering, 426 cases, 210 controls and 0 missing 
After filtering, 199 males, 437 females, and 0 of unspecified sex 
Converting data to Individual-major format 
Clustering individuals based on genome-wide IBS 
Merge distance p-value constraint = 0 
Reading genome-wide IBS estimates from [ FIND_AA_5plus_ibd.genome ]  
Of these, 201930 are pairable based on constraints 
Writing cluster progress to [ plink.cluster0 ] 
Writing cluster solution (1) [ plink.cluster1 ] 
Writing cluster solution (2) [ plink.cluster2 ] 
Writing cluster solution (3) [ plink.cluster3 ] 
Writing MDS solution to [ plink.mds ]  
MDS plot of individuals (not clusters) 
 
Analysis finished: Sun Aug 09 21:39:37 2015 
 
21) All_AA_Z4_removed.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
150 
 
Connecting to web...  OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ All_AA_Z4_removed.log ] 
Analysis started: Mon Oct 19 21:15:39 2015 
 
Options in effect: 
 --bfile 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed 
 --remove Z_4_ol.txt 
 --make-bed 
 --out All_AA_Z4_removed 
 
Reading map (extended format) from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bim ]  
782810 markers to be included from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bim ] 
Reading pedigree information from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.fam ]  
636 individuals read from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.fam ]  
636 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
426 cases, 210 controls and 0 missing 
199 males, 437 females, and 0 of unspecified sex 
Reading genotype bitfile from [ 
FIND_AA_5plus_sex_imputed_people_snp_t1d_PI_HAT_MAF0.05_HWE0.0001_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Reading individuals to remove [ Z_4_ol.txt ] ... 1 read 
1 individuals removed with --remove option 
Before frequency and genotyping pruning, there are 782810 SNPs 
635 founders and 0 non-founders found 
54 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ All_AA_Z4_removed.hh ] 
Total genotyping rate in remaining individuals is 0.998718 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 782810 SNPs 
After filtering, 426 cases, 209 controls and 0 missing 
After filtering, 199 males, 436 females, and 0 of unspecified sex 
Writing pedigree information to [ All_AA_Z4_removed.fam ]  
Writing map (extended format) information to [ All_AA_Z4_removed.bim ]  
Writing genotype bitfile to [ All_AA_Z4_removed.bed ]  
Using (default) SNP-major mode 
 
Analysis finished: Mon Oct 19 21:16:58 2015 
 
22) All_AA_Z4_assoc.log 
@----------------------------------------------------------@ 
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|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Connecting to web...  failed connection 
 
Problem connecting to web 
 
Writing this text to log file [ All_AA_Z4_assoc.log ] 
Analysis started: Tue Oct 20 14:12:01 2015 
 
Options in effect: 
 --bfile All_AA_Z4_removed 
 --assoc 
 --ci 0.95 
 --out All_AA_Z4_assoc 
 
Reading map (extended format) from [ All_AA_Z4_removed.bim ]  
782810 markers to be included from [ All_AA_Z4_removed.bim ] 
Reading pedigree information from [ All_AA_Z4_removed.fam ]  
635 individuals read from [ All_AA_Z4_removed.fam ]  
635 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
426 cases, 209 controls and 0 missing 
199 males, 436 females, and 0 of unspecified sex 
Reading genotype bitfile from [ All_AA_Z4_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Before frequency and genotyping pruning, there are 782810 SNPs 
635 founders and 0 non-founders found 
54 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ All_AA_Z4_assoc.hh ] 
Total genotyping rate in remaining individuals is 0.998718 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 782810 SNPs 
After filtering, 426 cases, 209 controls and 0 missing 
After filtering, 199 males, 436 females, and 0 of unspecified sex 
Writing main association results to [ All_AA_Z4_assoc.assoc ]  
 
Analysis finished: Tue Oct 20 14:13:18 2015 
 
23) All_AA_Z4_assoc_adjust.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
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|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found...Problem connecting to web 
 
Writing this text to log file [ All_AA_Z4_assoc_adjust.log ] 
Analysis started: Tue Oct 20 14:14:45 2015 
 
Options in effect: 
 --bfile All_AA_Z4_removed 
 --assoc 
 --ci 0.95 
 --adjust 
 --out All_AA_Z4_assoc_adjust 
 
Reading map (extended format) from [ All_AA_Z4_removed.bim ]  
782810 markers to be included from [ All_AA_Z4_removed.bim ] 
Reading pedigree information from [ All_AA_Z4_removed.fam ]  
635 individuals read from [ All_AA_Z4_removed.fam ]  
635 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
426 cases, 209 controls and 0 missing 
199 males, 436 females, and 0 of unspecified sex 
Reading genotype bitfile from [ All_AA_Z4_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Before frequency and genotyping pruning, there are 782810 SNPs 
635 founders and 0 non-founders found 
54 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ All_AA_Z4_assoc_adjust.hh ] 
Total genotyping rate in remaining individuals is 0.998718 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 782810 SNPs 
After filtering, 426 cases, 209 controls and 0 missing 
After filtering, 199 males, 436 females, and 0 of unspecified sex 
Writing main association results to [ All_AA_Z4_assoc_adjust.assoc ]  
Computing corrected significance values (FDR, Sidak, etc) 
Genomic inflation factor (based on median chi-squared) is 1.03567 
Mean chi-squared statistic is 1.03908 
Correcting for 782810 tests 
Writing multiple-test corrected significance values to [ All_AA_Z4_assoc_adjust.assoc.adjusted ]  
 
Analysis finished: Tue Oct 20 14:16:19 2015 
 
24) Quantitative_All_AA_Z4_qassoc.log 
@----------------------------------------------------------@ 
153 
 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found... OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ Q_All_AA_Z4_qassoc.log ] 
Analysis started: Fri Oct 23 19:13:43 2015 
 
Options in effect: 
 --bfile All_AA_Z4_removed 
 --pheno GFR_Phen.txt 
 --assoc 
 --ci 0.95 
 --qt-means 
 --out Q_All_AA_Z4_qassoc 
 
Reading map (extended format) from [ All_AA_Z4_removed.bim ]  
782810 markers to be included from [ All_AA_Z4_removed.bim ] 
Reading pedigree information from [ All_AA_Z4_removed.fam ]  
635 individuals read from [ All_AA_Z4_removed.fam ]  
635 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
426 cases, 209 controls and 0 missing 
199 males, 436 females, and 0 of unspecified sex 
Reading genotype bitfile from [ All_AA_Z4_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Reading alternate phenotype from [ GFR_Phen.txt ]  
632 individuals with non-missing alternate phenotype 
Assuming a quantitative trait 
Missing phenotype value is -9 
Before frequency and genotyping pruning, there are 782810 SNPs 
635 founders and 0 non-founders found 
54 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ Q_All_AA_Z4_qassoc.hh ] 
Total genotyping rate in remaining individuals is 0.998718 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 782810 SNPs 
After filtering, 632 individuals with non-missing status 
After filtering, 199 males, 436 females, and 0 of unspecified sex 
Writing QT association results to [ Q_All_AA_Z4_qassoc.qassoc ]  
Writing QT genotypic means to [ Q_All_AA_Z4_qassoc.qassoc.means ]  
 
Analysis finished: Fri Oct 23 19:15:49 2015 
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25) Quantitative_All_AA_Z4_qassoc_adjust.log 
@----------------------------------------------------------@ 
|        PLINK!       |     v1.07      |   10/Aug/2009     | 
|----------------------------------------------------------| 
|  (C) 2009 Shaun Purcell, GNU General Public License, v2  | 
|----------------------------------------------------------| 
|  For documentation, citation & bug-report instructions:  | 
|        http://pngu.mgh.harvard.edu/purcell/plink/        | 
@----------------------------------------------------------@ 
 
Web-based version check ( --noweb to skip ) 
Recent cached web-check found... OK, v1.07 is current 
 
+++ PLINK 1.9 is now available! See above website for details +++  
 
Writing this text to log file [ Q_All_AA_Z4_qassoc_adjust.log ] 
Analysis started: Fri Oct 23 19:18:21 2015 
 
Options in effect: 
 --bfile All_AA_Z4_removed 
 --pheno GFR_Phen.txt 
 --assoc 
 --ci 0.95 
 --adjust 
 --qt-means 
 --out Q_All_AA_Z4_qassoc_adjust 
 
Reading map (extended format) from [ All_AA_Z4_removed.bim ]  
782810 markers to be included from [ All_AA_Z4_removed.bim ] 
Reading pedigree information from [ All_AA_Z4_removed.fam ]  
635 individuals read from [ All_AA_Z4_removed.fam ]  
635 individuals with nonmissing phenotypes 
Assuming a disease phenotype (1=unaff, 2=aff, 0=miss) 
Missing phenotype value is also -9 
426 cases, 209 controls and 0 missing 
199 males, 436 females, and 0 of unspecified sex 
Reading genotype bitfile from [ All_AA_Z4_removed.bed ]  
Detected that binary PED file is v1.00 SNP-major mode 
Reading alternate phenotype from [ GFR_Phen.txt ]  
632 individuals with non-missing alternate phenotype 
Assuming a quantitative trait 
Missing phenotype value is -9 
Before frequency and genotyping pruning, there are 782810 SNPs 
635 founders and 0 non-founders found 
54 heterozygous haploid genotypes; set to missing 
Writing list of heterozygous haploid genotypes to [ Q_All_AA_Z4_qassoc_adjust.hh ] 
Total genotyping rate in remaining individuals is 0.998718 
0 SNPs failed missingness test ( GENO > 1 ) 
0 SNPs failed frequency test ( MAF < 0 ) 
After frequency and genotyping pruning, there are 782810 SNPs 
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After filtering, 632 individuals with non-missing status 
After filtering, 199 males, 436 females, and 0 of unspecified sex 
Writing QT association results to [ Q_All_AA_Z4_qassoc_adjust.qassoc ]  
Writing QT genotypic means to [ Q_All_AA_Z4_qassoc_adjust.qassoc.means ]  
Computing corrected significance values (FDR, Sidak, etc) 
Genomic inflation factor (based on median chi-squared) is 1.00698 
Mean chi-squared statistic is 1.01439 
Correcting for 782810 tests 
Writing multiple-test corrected significance values to [ Q_All_AA_Z4_qassoc_adjust.qassoc.adjusted ]  
 
Analysis finished: Fri Oct 23 19:21:04 2015 
 
 
